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ABSTRACT 
 
Synthesis and Characterization of Covalently-Linked Dendrimer Bioconjugates and the 
Non-Covalent Self-Assembly of Streptavidin-Based Megamers. (December 2004) 
Megan E. McLean, B.S., State University of New York College at Fredonia 
Chair of Advisory Committee: Dr. Eric E. Simanek 
 
This work details the attachment of dendrimers to proteins, peptides and single 
stranded DNA (ssDNA). Dendrimers based on melamine satisfy many of the synthetic 
demands in the field of bioconjugate chemistry including: monodispersity, synthetic 
flexibility and scalability. The solution-phase syntheses of both ssDNA-dendrimer and 
peptide-dendrimer bioconjugates is described, and thorough characterization by matrix-
assisted laser desorption ionization/ time-of-flight (MALDI-TOF) mass spectrometry, 
UV-vis spectroscopy, fluorescence spectroscopy, and polyacrylamide gel electrophoresis 
is discussed. 
Non-covalent DNA-dendrimer complexes have been shown to facilitate antisense 
gene delivery, but are vulnerable to dissociation and subsequent enzymatic degradation 
within the cell. In an effort to prepare biocompatible antisense agents capable of 
effectively shielding ssDNA from intracellular nuclease digestion, disulfide-linked 
ssDNA-dendrimers were prepared and rigorously characterized to rule out the possibility 
of an electrostatic-based interaction.  
Hybridization assays were performed to determine if the covalently-attached 
dendrimer affected the ability of the attached ssDNA strand to anneal with a 
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complementary sequence to form double-stranded DNA (dsDNA)-dendrimers. Results 
indicate that ssDNA-dendrimer conjugates readily anneal to complementary ssDNA 
strands either in solution or attached to gold surfaces. Nuclease digestions of conjugates 
in solution suggested that enzymatic manipulation of dsDNA-dendrimers is possible, 
offering promise for DNA-based computation and other fields of DNA-nanotechnology. 
Much larger bioconjugates consisting of dendrimers, proteins and peptides were 
prepared with the goal of obtaining molecular weights sufficient for enhanced 
permeability and retention (EPR) in tumors. While the dendrimer provides the advantages 
of a purely synthetic route for drug delivery, the protein portion of the bioconjugate 
provides a monodisperse, macromolecular scaffold for the non-covalent self-assembly of 
the dendrimers. The strategy presented herein is based on the strong interaction between 
biotin and the 60 kD tetrameric protein streptavidin. Each monomer of streptavidin is 
capable of binding 1 biotin molecule, thus when biotin functionalized peptide-dendrimers 
are added to streptavidin they bind to form a cluster of dendrimers, or a megamer.  
The biotinylated peptides that link the dendrimers to the streptavidin core provide 
a way to actively target specific cell types for drug delivery. Megamer formation through 
the addition of tetrameric streptavidin was successful as indicated by MALDI-TOF, UV-
vis titration and gel electrophoresis assays.     
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CHAPTER I 
INTRODUCTION 
 
BACKGROUND 
 
Dendrimer background.  The first known dendrimers, initially called cascade 
molecules were reported by Vögtle and coworkers in 1978.1 Since then, the prevalence of 
dendrimers in the literature has reached over 4,000 research articles and reviews (up from 
only a small handful in 1996), and the impact they will make in nanobiotechnology and 
pharmaceutics is just beginning to be realized. Dendritic molecules have made significant 
contributions in many fields including but not limited to: drug delivery,2-7 protein 
mimicry,8,9 gene transfection,10-13 materials and coatings,14-20 sensors and detectors,21-25 
patterning and templating,26-29 adhesives,30,31 image contrast agents,32-34 optics and optical 
films,35-38 quantum dots and nano dots,39-42 catalysis,43-47 and separations.48-50 
Structurally, dendrimers are globular synthetic macromolecules that branch out 
from a central core. They are synthesized in layers, in a stepwise fashion, to yield a 
monodisperse (or nearly monodisperse, depending on the chemical nature of the 
peripheral functional groups) polymer with a high degree of symmetry and a well defined 
size. Dendrimers consist of three structural units: (1) the core, (2) branching units and (3) 
peripheral groups. There are two general synthetic routes toward dendrimers: (A) 
divergent and (B) convergent. As shown in Scheme 1-1, either method allows for some 
level of control over the number and type of functional groups along the periphery, or 
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outermost layer, such that the peripheral functional groups may be chemically distinct 
from the interior groups.  
 
Scheme 1-1
 
= core 
 
= branching group 
 
= peripheral group 
A B 
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Starburst dendrimers, introduced by Tomalia,51,52 are prepared using a divergent 
synthetic strategy. Scheme 1-2 shows the layer-by-layer branching pattern of a starburst 
polyamidoamine (PAMAM) dendrimer. Each layer (or generation) of a dendrimer is 
noted by GX, where X is the number of chemical layers, or branching groups, counting 
out from the core, which in this case is ethylenediamine. 
 
 
Scheme 1-2 
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Benefits of convergent synthesis.  Fréchet and coworkers53 introduced the 
convergent approach to dendrimer synthesis. The convergent approach, though less 
popular in industry, allows for greater control over the regiospecific display of the 
peripheral groups. Due to the differential reactivity of the core molecule, asymmetrical 
dendrimers are more readily prepared by using a convergent approach, than when 
building from the inside out, or divergently. The convergent synthesis of a dendrimer is 
compared to that of a divergent approach in Scheme 1-1. In the convergent approach, a 
multifunctional core molecule is reacted with peripheral functional groups or dendrons 
(the term dendron is loosely designated for an incomplete dendrimer). The product is 
purified if necessary, and a new core molecule is used to link together the newly formed 
intermediate dendrons. The process is repeated until the desired target has been 
synthesized. Depending on the valency of the core molecule, a dendron could structurally 
comprise of half of a dendrimer, one forth, and so on.  
The number of reactions per growth step is constant in the convergent approach, 
whereas in the divergent approach, the number of reactions per growth step increases 
with the increasing number of peripheral groups per generation. It is also generally easier 
to separate out the intermediate byproducts at each growth step when using the 
convergent approach. To illustrate this generalization, one possible byproduct arising 
from an incomplete reaction during (A) divergent synthesis and (B) convergent synthesis 
of a dendrimer are shown in Scheme 1-3. Given the simplest scenario where all of the 
peripheral groups are the same, it is easier to achieve chromatographic separation solely 
based on the retention factor of the desired intermediate compared to that of the 
byproduct in (B) using the convergent approach than in (A) using the divergent approach. 
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When some peripheral groups are different creating a heterogeneous outermost layer, it 
becomes increasingly difficult to separate out the many possible side products formed in 
a divergent approach. 
Scheme 1-3 
 
 
 
 
 
Dendrimers based on melamine.  Dendrimers based on melamine are ideally 
suited for the convergent approach since the core molecule, triazine trichloride (cyanuric 
chloride), offers differential control of nucleophilic aromatic substitution at each of the 
three reactive sites.54 The phrase “dendrimers based on melamine” is derived from the 
melamine core that is formed when all three chlorides of the triazine are displaced with 
amine groups. Scheme 1-4 demonstrates how three chemically unique amines may be 
added to cyanuric chloride. Differential reactivity is manipulated in two ways, 
temperature and nucleophilicity. The differential reactivity of cyanuric chloride with 
various amines has been demonstrated by Steffensen and Simanek.55   
 
A B
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Scheme 1-4 
 
 
 
Synthetically, the advantage of using dendrimers based on melamine lies in the 
ability to diversify the chemical functionality not only from one generation to the next, 
but also site-specifically within the layers without having to rely on elaborate and 
strategic protecting group manipulations. The temperature-controlled addition of primary 
or secondary amines to cyanuric chloride allows for the attachment of three chemically 
unique substituents around the triazine core. For primary amines, the first addition occurs 
at 4 °C on ice, the second adduct forms at room temperature, and the third addition 
requires a degree of heat dependent upon the reactivity of the amine (usually ~ 70º C). 
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with cyanuric chloride. Precautions must be taken, however, to avoid the dimerization of 
two core molecules via the diamine. The addition of diamines with differential reactivity 
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dimerization events. Scheme 1-5 illustrates how the reactivity of a benzylic amine 
relative to aniline (benzyl amine >> aniline) can be utilized in the convergent approach to 
prevent the formation of dendrimeric byproducts wherein both amines on the newly 
introduced diamine react with 2 equivalents (eq.) of monochloride triazine, forming a 
dimer. This synthetic route also demonstrates how both temperature and amine reactivity 
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can be used to place different R groups along the periphery in a regiospecific manner 
without the use of protecting group strategies.  
 
Scheme 1-5 
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and restrict cellular uptake to an endocytosis-mediated pathway. Since macromolecules 
are unable to diffuse passively into cells, they are instead engulfed as membrane-
encircled sacs (vesicles). The increased size of the drug-polymer conjugate decreases 
clearance through the kidneys, so the polymer-drug conjugate should circulate longer. 
Ringsdorf hypothesized that with the appropriate biodegradable linker and/or a cell-
specific targeting group, it would be possible to deliver the drug directly to the targeted 
site avoiding the toxic side-effects associated with many drugs. 
Over the last 25 years many advances in the field of responsive polymers have 
been reported,57-59 and polymers that respond to: magnetic, electric, or ultrasound stimuli, 
temperature, pH, ionic strength, or even glucose levels have been reported.60 Despite 
significant advances in time-controlled polymeric drug release, the synthetic challenges 
involved in engineering polymers with a high therapeutic index, low toxicity, and low 
immunogenicity have proven difficult to overcome.61  
 
Scheme 1-6 
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Dendrimers are ideally suited to satisfy Ringsdorf’s idea. Indeed, the synthetic 
focus in polymeric therapeutics has broadened from using linear polymers to control drug 
release and prolong the drug’s lifetime through lengthened circulation to include three 
other important properties: (1) monodispersity, (2) size, and (3) presentation of several 
different reactive sites for the conjugation of targeting and transport groups.  
Importance of monodispersity.  Currently, all polymeric drug delivery systems 
in clinical trials and on the market are polydisperse systems.61  A polydisperse polymer 
system is one in which there is a distribution of molecular weights present. A 
monodisperse system would have only one molecular weight present. Polydispersity can 
be defined as the ratio of weight average molecular weight (Mw) to number average 
molecular weight (Mn), or Mw/Mn, where Mw/Mn ≥ 1 . Mn is determined by counting the 
number of species with a particular molecular weight (MW) and multiplying by the MW. 
The values are then summed and divided by the total number of polymer species present 
in the sample. Mw can be obtained by recording the weights of the species present in the 
sample, summing these weights, and dividing by the total weight of the sample. Low 
polydispersity of a drug carrier system allows for more predictable pharmacokinetic 
properties since there are fewer versions of the molecule rather than a range, and their 
fates can be more easily tracked in vivo. As early as 1976, Breslow pointed out that each 
distinct molecular weight in a polymeric range produced a unique biological response.62 
Although recent advances in atom transfer radical polymerization techniques have 
allowed for nearly monodisperse product formation,63 enzymatic breakdown or other 
biologically-mediated polymer degradation can result in the release of various molecular 
weight polymers with potential for producing an immunological response.64 Thus the 
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synthesis of a monodisperse polymer for use in drug delivery, while essential for 
evaluation of drug metabolism and pharmacokinetics (DMPK), may not necessarily 
afford biocompatibility. The polymer and subsequent degradation products must also be 
biologically inert. Even with well-accepted polymer-drug delivery systems such as 
polyethylene glycol (PEG)-grafted liposome delivery agents, immunotoxicity and 
fatalities through anaphylactic shock have been reported.65 From a synthetic standpoint, 
another benefit of monodispersity is that the products may be more rigorously 
characterized. Current separation techniques do not allow for the isolation of a 
monodisperse polymers from standard polymerization protocols. 
Importance of size.  The size of the drug carrier is an important factor when 
considering the delivery of therapeutics for the treatment of cancer. Expression and 
secretion of Vascular Endothelial Growth Factor-A (VEGF-A) by tumor cells induces 
leakiness and dilation of tumor blood vessels resulting in a phenomenon known as 
enhanced permeability and retention, or the EPR effect.66 As a result, tumor tissue tends 
to take up larger molecules at a faster rate than normal tissue, and due to poor lymphatic 
drainage, molecules that are taken up are also retained. Scheme 1-7 represents how the 
EPR effect works. The leaky vasculature of blood vessels in cancerous tissue causes the 
polymer-drug conjugates to seep out into the tumor tissue. Poor lymphatic drainage traps 
the polymer-drugs within the tumor tissue while the intact vasculature of blood vessels 
found in healthy tissue precludes the conjugates from seeping into non-cancerous tissue. 
Molecules that are at least 40 kDa demonstrate enhanced permeability and retention in 
tumors. Various polymeric drug delivery systems have been designed that take advantage 
of the hyperpermeable vasculature of solid tumors.67 
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Scheme 1-7 
 
 
 
Importance of targeting and transport groups.  Cancer cells can be 
differentiated from healthy cells by the receptors that are displayed on the periphery. For 
example, tumors are known to overexpress receptors for various growth hormones, lipids, 
and vitamins, many of which bind to specific ligands. Folate has been used to target the 
overexpressed folate receptor on tumor cells, for example.68 Roughly 30% of cancerous 
cells including ovarian, kidney, most brain, some types of lung, and many breast cancer 
cells overexpress folate receptors, but most colon cancers and prostate cancers do not. 
Thus the need for a synthetically flexible drug carrier is clear, as there will never be one 
magic bullet for all cancers.  Most drugs are selective for a particular signaling pathway 
that may or may not predominate in all cancer types at all stages of cancer development. 
Thus, there is an emerging interest in combination drug therapy to target several different 
proteins in a particular signaling pathway, and/or aim for different cell types in cancer 
development as a way to produce more effective anti-cancer agents.69 This strategy 
provokes interest in expanding upon Ringsdorf’s model by adding several different types 
of targeting or drug agents on a single macromolecular, monodisperse carrier. 
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Dendrimer-drug delivery.  Dendrimers represent an interesting solution to the 
collective challenges of monodispersity, size, and specific targeting ability, especially 
since in vivo studies suggest they are relatively non-toxic and demonstrate low 
immunogenicity.70 Most current dendrimer-drug conjugates focus on host-guest 
interactions of the drug which is encapsulated within the gaps on the interior of the 
dendrimer. The micellar character of dendrimers with amphiphilic moieties permit 
entrapment of drugs without the instability of traditional micelles which fall apart at 
concentrations below the critical micellar concentration (cmc).71 Hawker et al.72 reported 
the solubilization of pyrene in water using poly(aryl ether) dendrimers with carboxylic 
acid peripheral groups, and Liu et al. used poly(ethylene glycol) (PEG) coated 
dendrimers with a hydrophobic core to solubilize pyrene.73 Meijer and coworkers 
presented the “dendritic box” in 199474 and later reported the shape selective release of 
the entrapped guests.75 Examples of covalently linked dendrimer-drugs conjugates and 
bioconjugates, however, are increasingly popular. Scheme 1-8 compares the “dendritic 
box” or micellar strategy of drug delivery to the covalent strategy wherein drugs are 
covalently attached to the surface groups of the dendrimer.76 Scheme 1-8 (A) shows 
entrapment of drug molecules within the interior gaps, and (B) shows covalent 
attachment of drug molecules to the periphery. 
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Scheme 1-8 
  
 
 
 
 
 
 
 
Fréchet and coworkers proposed a model for dendrimer-mediated drug delivery 
similar to the one shown in Scheme 1-9. Ideally, the dendrimer would have solubilizing 
groups attached to the majority of the surface with several drug molecules and a targeting 
agent such as an antibody or antigen-specific peptide. 
 
Scheme 1-9 
 
 
 
 
 
 
 
 
= solubilizing agent 
 
= targeting agent 
 
= drug 
 
= cleavable linker 
= drug molecule 
A B 
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The synthesis required for the preparation of dendrimers that are large enough to 
demonstrate EPR in tumors still represents a significant burden. Appending polyethylene 
glycol (PEG) chains to increase the size of smaller dendrimers represents a covalent 
solution to this burden. Since PEG chains are polydisperse, however, any clinical and/or 
synthetic benefits that may be reaped from using a monodisperse drug delivery agent 
could be lost by adding PEG chains. 
DNA-dendrimer bioconjugates.  Modern molecular biology techniques allow us 
to both program intreractions between DNA strands according to Watson-Crick base-pair 
complementarity and manipulate DNA using a number of different sequence specific 
enzymes. These techniques have brought oligonucleotides to the forefront of 
nanotechnology.77  DNA has been used to construct: templates for computation,78,79 self-
assembled two-dimensional crystals80,81 and three dimensional objects,82 nano-devices, 
83,84 nano-motors,85-87 biosensors88 and electrical circuits.89,90 Dendritic DNA 
nanostructures have been constructed to expand the capabilities of DNA nanotechnology 
through polyvalent oligonucleotide display.91 The use of DNA constructs in the 
aforementioned DNA-machines, DNA-computing, antisense therapy, and biosensors has 
fueled intense research into suitable methods for immobilizing DNA on surfaces and 
preparing soluble DNA-nanoparticle assemblies. Multiple ssDNA oligonucleotides have 
been attached to soluble organic polymers and gold nanoparticles, but methods for the 
covalent attachment of individual ssDNA oligonucleotides to soluble nanoparticles are 
surprisingly rare.92 Dendrimers based on melamine provide a tractable scaffold for 
controlled covalent functionalization of dendrimers with ssDNA. 
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Disulfide-linked DNA-dendrimer conjugates, introduced in Chapter II, establish 
an inexpensive, chemically flexible DNA-dendrimer synthetic strategy based on the 
temperature controlled reactivity of cyanuric chloride as shown in Schemes 1-2 and 1-3. 
An unparalleled level of synthetic diversity exists with these systems in which some 
specified number of unique oligonucleotide sequences may be covalently and site-
specifically linked to various chemically unique dendrimers. Control over the 
chemoselective addition and cleavage of application-specific chemical handles like 
fluorophores or polypeptides to and from the dendrimer may be further accomplished 
through strategic protecting group manipulations. This work presents the first example of 
a strategy that simultaneously offers a high degree of control over charge, size, solubility, 
interior composition and peripheral attachment chemistry.  
Focusing on biosensors and diagnostics, methods for the rapid and accurate 
detection of biological targets (in the identification of biological warfare agents, for 
example) are in high demand. Previous signal enhancement methods for ssDNA detection 
have relied on expensive labels, radiological tags, or secondary signal enhancement such 
as rolling circle amplification. Nanoparticle-based probes for solution-phase and surface 
array ssDNA detection have made progress in this field, but usually require gold surfaces 
or self-assembled monolayers as the support.  
Of particular interest is the ability of cationic dendrimers to charge neutralize 
anionic DNA, allowing for cellular uptake for gene therapy.93 Covalent, reversible DNA-
dendrimer linkages such as disulfides could prove to shelter the antisense strand from 
intracellular enzymatic degradation without compromising biocompatability. A general 
representation of how antisense gene therapy works to prevent the biological synthesis of 
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disease-related proteins is shown in Scheme 1-10. Typically the antisense agent binds to 
the messenger RNA (mRNA) preventing it from associating with the ribosome during 
translation thereby halting the biosynthesis of the deleterious protein. Other mechanisms 
of gene therapy exist, for example in the formation of a triple helix prior to transcription 
preventing formation of the corresponding mRNA strand. Regardless of the exact 
mechanism of action, however, all antisense delivery agents must be able to transfer the 
therapeutic DNA strand (or antisense drug) across the cell membrane and protect the 
attached oligonucleotide from enzymatic degradation within the cell. When targeting the 
disease-related gene at the transcriptional level, the agent must also afford passage 
through the nuclear membrane and stability within the nucleus.  
 
Scheme 1-10 
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Plasmid DNA is too large and negatively charged to penetrate the cell membrane 
in naked form,94 and internalized plasmid DNA is quickly degraded by intracellular 
enzymes.95,96 Symmetrical, polycationic dendrimers such as polyamidoamine (PAMAM) 
dendrimers have been extensively studied for their ability to transport therapeutic DNA 
across biological membranes.97 The ability of “polyplexes” or electrostatically-linked 
polycation-DNA conjugates to dissociate, however, could be one explanation for their 
limited usefulness in antisense gene delivery. 
Peptide-dendrimer bioconjugates.  A review of peptide dendrimers, written by 
Sadler and Tam,98 summarizes several proposed uses for peptide-dendrimer 
bioconjugates and discusses the three general classes: (1) grafted peptide dendrimers with 
unnatural amino acid-based or organic-based cores and peptide or protein-based surface 
functional groups, (2) branching polyamino acids (usually lysine) with terminal amino 
acids acting as surface groups, and (3) amino acid branching units with surface peptidyl 
chains. The most common example of the last type of peptide dendrimer is the multiple 
antigen peptide (MAP) which has been used extensively to stimulate an immune response 
or probe antigen-antibody interactions. 
The primary reasons for creating peptide-dendrimer bioconjugates are for drug 
delivery and biomedical applications such as MRI contrasting agents.25 While peptides 
can act as therapeutic agents in their own right, they may also be used to target specific 
cell types99,100 or aid in transport through the cell membrane. Wender and coworkers have 
determined the most efficient peptide sequences for use as cell penetrating carriers to 
attach cargo for intracellular delivery. Several researchers have since incorporated the 
arginine-rich sequence referred to as “TAT” (transactivator of transcription) into their 
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drug delivery vehicles. Protein transduction domains like TAT have been either 
genetically or chemically linked to proteins, antibodies, nucleic acids, liposomes, 
nanoparticles and small molecules to affect their transfer into cells. The TAT peptide is a 
protein transduction domain from HIV-1 that aids in the translocation of viral genetic 
material across the cell membrane. Although the mechanism of this transport remains 
unknown, the portion of the TAT protein required for translocation consists of residues 
49-57 (RKKRRQRRR). This highly basic domain facilitates cell surface recognition and 
protects the transferred material from lysosomal degradation. TAT has also been used to 
carry attached cargo into the nucleus.  
Biotin serves as a natural ligand for the tetrameric, 60 kDa protein streptavidin 
with a dissociation constant of 10-15 M. Upon addition of streptavidin to a biotinylated 
macromolecular drug delivery agent, each streptavidin monomer would theoretically bind 
one biotin such that four biotinylated molecules would self assemble around each 
streptavidin tetramer. The additional bulk provided by the streptavidin would increase the 
molecular weight of the drug carrier system into the required size range to observe an 
EPR effect in tumor tissue. Since proteins are in essence monodisperse polymers, the 
resulting bioconjugates formed through the highly specific and robust biotin-streptavidin 
interaction would provide a promising route toward anti-cancer drug delivery.   
Supramolecular dendrimers and megamers.  Naturally existing biological 
macromolecules often provide inspiration for synthetic supramolecular architectures. 
Dendrimers are especially useful as building blocks for functional materials and as 
mimics of globular proteins.101,102 Percec and coworkers prepared insulated, self-
assembled electrical wires resembling the DNA double helix where electrically 
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conducting small molecules take the place of the base pairs, and dendrimers take the 
place of the sugar-phosphate backbone.103 Dendrimers have been used as cages to 
produce coenzyme B12 mimics104 and as capping agents to produce spatially encumbered 
models of non-heme iron proteins.9 Balzani and coworkers have used coordination 
chemistry to produce complex redox-active, luminescent, and fluorescent architectures 
using dendrimers.105,106 Dendritic building blocks that assemble due to hydrogen-bonding 
interaction have been described by Zimmerman and coworkers.107  Hydrogen-bonding-
based molecular recognition has been used to prepare a dendritic framework for use in 
site-specific molecular recognition, guest(s) encapsulation and solubilization.108  
The generic term megamer was first used by Tomalia and coworkers to describe a 
cationic dendrimer core surrounded by excess anionic shell dendrimers to form a charge 
neutral “core-shell (tecto)dendrimer”.109 A “sphere upon sphere” model of a megamer is 
shown in Scheme 1-11. Megamers, as presented by Tomalia are nearly monodisperse 
assemblies that are held together covalently.  
 
Scheme 1-11 
 
 
 
Other examples of noncovalent macromolecular synthesis rely on naturally 
occurring biopolymers. A notable example is the preparation of DNA-based architectures 
(NH2)n + CO2H 
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that assemble into polyhedra of predetermined shape.110 Whitesides and coworkers 
reported the synthesis of monodisperse polymers from proteins.111  Padilla and coworkers 
have reported self assembling protein cages, layers, crystals and filaments.112 
Proteins offer a monodisperse scaffold for macromolecular syntheses that 
bypasses the need to attach chemically synthesized polymers to drug carrier systems in 
order to achieve EPR in tumors.  The ability of proteins to bind natural ligands, for 
example streptavidin to biotin, leads us to explore the preparation of self-assembling 
megamers. Megamers based on the streptavidin-biotin interaction, unlike Tomalia’s core-
shell megamers, would be monodisperse and held together non-covalently.  
In closing, the important issues of monodispersity, size, and targeting of 
macromolecular drug delivery systems may be addressed using various macromolecular 
bioconjugates of dendrimers based on melamine. The chemical flexibility of dendrimers 
based on melamine lends itself to bioconjugate formation with drug molecules such as 
antisense genes, targeting moieties such as peptides, and proteins as macromolecular 
scaffolds.  
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CHAPTER II 
 
SOLUTION-PHASE SYNTHESIS AND CHARACTERIZATION OF DISULFIDE-
LINKED DNA-DENDRIMER BIOCONJUGATES 
 
BACKGROUND 
 
Using thiol/disulfide exchange chemistry, thiol-terminated 12-base single 
stranded DNA sequences with or without an Oregon Green fluorophore attached 
(purchased in C18 HPLC-purified form from Trilink Biotechnologies, Inc.) were added to 
second- and third-generation triazine-based dendrimers. The synthesis permits either one 
or two single-stranded DNA (ssDNA) oligonucleotides to be covalently attached to the 
dendrimer at the core, the periphery, or both as depicted in Table 2-1. 
DNA-dendrimer conjugates from Table 2-1 will be referred to as AI, AII, AIII, 
BI, BII, and BIII, for convenience. A method for HPLC purification of AII is presented 
with subsequent peak assignments by MALDI-TOF. Further structure elucidation of BII 
was made possible through labeling analysis using Ellman's reagent, and degradation 
analysis with a reducing agent. Proof of structure for all other architectures was derived 
primarily from mass spectrometry and polyacrylamide gel electrophoresis was performed 
whenever yields permitted.  
Most of the conjugates in Chapter II were prepared from 12-mer ssDNA. Two of 
the conjugates, AI and BIII, consisted of 31-mer ssDNA and 22-mer ssDNA, 
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respectively. These longer conjugates were prepared in order to study the hybridization 
behavior of these conjugates with surface bound probe ssDNA in Chapter III.  
 
Table 2-1. Targets arising from disulfide exchange between ssDNA and dendrimer. 
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EXPERIMENTAL PROCEDURES 
 
Materials. Reagent grade chloroform, methylene chloride, methanol, and ethyl 
acetate were used without further purification during synthesis. THF was dried over 4Ǻ 
molecular sieves prior to use in synthesis. All deuterated solvents used were purified in 
the same manner as the non-deuterated equivalent after being received from Cambridge 
Isotope Laboratories (Cambridge, MA). Cyanuric chloride (98%), DIPEA (99%), and 
piperazine (99+%) were used as supplied by Acros (Pittsburgh, PA). Dansyl chloride 
(98+%) was used as supplied by Aldrich (Milwaukee, WI). Sulfosuccinimidyl 4-(N-
maleimidomethyl)cyclohexane-1-carboxylate (SSMCC, Pierce), tris(2-
carboxyethyl)phosphine, HCl (TCEP-HCl, Pierce),  triethanolamine (TEA, 98%, Aldrich 
Chemical Co.), NaH2PO4 (99%, Mallinckrodt AR), ethylenediaminetetra acetic acid 
(EDTA, 100%, Sigma), sodium dodecylsulfate (SDS, 99%, Fluka Chemie AG), and NaCl 
(EM Science) were used as received.  Ultrapure 18 MΩ·cm Milli-Q water was used to 
prepare buffer solutions and to rinse.  Immobilized tris(carboxyethyl)phosphine (TCEP) 
and succinimidyl 3-(2-pyridylthio)propionate (SPDP) were used as purchased from 
Pierce Chemical (Rockford, IL). Electrophoresis grade acrylamide:bisacrylamide (29:1), 
ethidium bromide (1% solution), and coomassie blue R250 were used as received from 
FisherBiotech (Pittsburgh, PA).  
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Trisborate EDTA (0.45 M) and 10× DNA gel loading buffer were purchased from 
Eppendorf (Hamburg, Germany). Disulfide-modified oligonucleotides were purchased 
from Trilink Biotechnologies (San Diego, CA). Nuclear magnetic resonance (NMR) 
spectra (1H and 13C) were recorded on a Varian 300 NMR spectrometer.  
Dendrimer synthesis. Syntheses of the dendrimers discussed in this chapter were 
aided by post doctoral group members Dr. Steven Bell and Dr. Wen Zhang. The synthesis 
of dendrimer 5, from Scheme 2-1, is reported below. Steps b, c, and d in Scheme 2-1 
describe the substitution of cyanuric chloride with three chemically unique amines. 
Experimental details for the preparation of dendrimer 5 are found below Scheme 2-1, and 
they clearly demonstrate the methodology behind the synthesis of dendrimers based on 
melamine. All other dendrimer syntheses for this work have been published.113,114 
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Scheme  2-1* 
 
 
 
*a) 1 eq. NH2CH2(CH2OCH2)3CH2NH2, 1 eq. dansyl chloride, DIPEA, dioxane, RT, 14 
h.; b) C3N3Cl3, DIPEA, THF, -6 ºC; c) BocNHCH2(CH2OCH2)3CH2NH2, DIPEA, THF, 
RT, 14 h.; d) Piperazine, DIPEA, THF, 70 ºC, 14 h.; e) C3N3Cl3, DIPEA, THF, RT, 14 h.; 
f) Piperazine, DIPEA, THF, 70 ºC, 14 h.; g) SPDP, DIPEA, THF, RT, 24 h.; h) 
Trifluoroacetic acid:CH2Cl2 (1:1), RT, 10 h.  
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Synthesis of 1. Dansyl chloride (1.306 g, 4.84 mmol) was added to a solution of 
NH2CH2(CH2OCH2)3CH2NH2 (5.58 g , 29.0 mmol) and DIPEA (1.7 mL, 5.03 mmol) in 
THF (100 mL). The resulting mixture was dried by centrifugal evaporation (in vacuo) 
and then partitioned between CH2Cl2 and water.  The organic phases were dried in vacuo, 
and concentrated in vacuo to yield a bright green oil which was purified via silica gel 
column chromatography (100:8, CH2Cl2:MeOH eluent). A bright green oil was obtained 
(1.260 g, 61.1 %). 1H NMR (300 MHz, CD3OD) 3.72 (tr, 4H, NCH2), 3.62 (m, 24H, 
CH2OCH2), 3.49 (tr, 4H,-C(O)NHCH2CH2), 3.20 (tr, 4H, NHCH2CH2), 2.79 (br, 4H, 
HNCH2), 1.42 (s, 18H, OC(CH3)3). 13C NMR (75 MHz, CD3OD) 166.2, 165.0, 157.1, 
78.9, 70.4, 53.9, 43.7, 43.0, 40.4, 27.8; MALDI-TOF (m/z): [M + H]+ calcd. for 
C33H63N9O10, 746.5; found, 746.8.  
Synthesis of 2. Compound 1, (0.906 g, 2.13 mmol) in THF (10 mL) was added 
drop-wise to a cooled (-6 °C), solution of cyanuric chloride (0.404 g, 2.13 mmol) and 
DIPEA (1.7 mL, 5.03 mmol) in THF (30 mL) while stirring. After 2 h the reaction 
mixture was warmed to room temperature and more DIPEA (1.5 mL, 4.84 mmol) was 
added, followed by a THF solution (15 mL) of BOC-NHCH2(CH2OCH2)3CH2NH2  
(0.622 g, 4.95 mmol). After stirring for 14 h at room temperature a pale green/yellow 
solution with white precipitate formed, yielding a single TLC spot (Rf = 0.78; 
DCM:MeOH, 5:1). A six-fold excess of piperazine (1.50 g, 12.8 mmol) and DIPEA (1.5 
mL, 4.84 mmol) was added, and the mixture was stirred for 14 h at room temperature.  
After concentrating the sample by vacuum centrifugation, the residue was partitioned 
between CH2Cl2 and water.  The organic phases were concentrated in vacuo to yield a 
bright green oil which was purified via silica gel column chromatography (100:5, 
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CH2Cl2:MeOH eluent). A pale green oil was obtained (1.10 g, 58.7 %). 1H NMR (300 
MHz, CD3OD) 8.2 (tr, 1H, o-CH), 7.75 (m, 2H, m-CH), 7.2 (tr, 1H, p-CH), 3.75 (br, 4H, 
NCH2) 3.63 (m, 12H, CH2OCH2), 3.50 (tr, 4H, C(O)NHCH2CH2 and NCH2CH2S), 3.21 
(tr, 2H, NHCH2CH2), 3.02 (tr, 2H, NCH2CH2S), 2.82 (br, 4H, NHCH2), 1.43 (s, 9H, 
OC(CH3)3). 13C NMR (75 MHz, CD3OD) 167.6, 166.1, 161.2, 150.1, 139.2, 122.6, 
121.2, 80.2, 71.4, 49.9, 46.3, 44.5, 41.4, 40.8, 39.6, 28.9; MALDI-TOF (m/z): [M + H]+ 
calcd for C27H45N9O5S2, 640.3; found, 640.4.  
Synthesis of 3. Dendrimer 2 (0.453 g, 0.516 mmol) was dissolved in THF (25 
mL), and added drop-wise to a cooled (-6 °C), THF solution (30 mL) of cyanuric chloride 
(0.046 g, 0.258 mmol) and DIPEA (0.75 mL, 2.42 mmol) while stirring. After 2 h the 
reaction mixture was warmed to room temperature. After stirring for 14 h at room 
temperature a pale green/yellow solution with white precipitate formed.  After removal of 
solvent, the residue was partitioned between CH2Cl2 and water.  The organic phases were 
concentrated in vacuo to yield a pale green/yellow oil which was purified via silica gel 
column chromatography (100:4, CH2Cl2: MeOH eluent). A green oil was obtained (0.251 
g, 50.7 % yield). 1H NMR (300 MHz, CD3OD) 8.2 (m, 1H, o-CH), 7.78 (m, 2H, m-CH), 
7.19 (tr, 1H, p-CH), 3.75 (br, 16H, NCH2), 3.62 (m, 36H, CH2OCH2), 3.50 (br, 8H, 
C(O)NHCH2CH2 and NCH2CH2S), 3.22 (m, 6H, NCH2) 3.04 (tr, 2H, NCH2CH2S), 1.43 
(s, 27H, OC(CH3)3); 13C NMR (75 MHz, CD3OD) 169.5, 166.1, 165.0, 164.4, 160.0 
157.0, 150.0, 137.8, 121.1, 119.8, 78.9, 71.2, 70.2, 43.5, 42.9, 40.3, 27.9. MALDI-TOF 
(m/z): [M + H]+ calcd for C63H10N21O9S2, 1495.5; found, 1495.8.  
Synthesis of 4. Dendrimer 3 (0.040 g, 0.021 mmol) was reacted with N-
Succinimidyl 3-[2-pyridyldithio]-propionamidoSPDP (0.066 g, 0.021 mmol) for 14 h at 
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RT in THF (10 mL). A green/yellow oil was obtained after solvent evaporation (0.032 g, 
72.0 %). 1H NMR (300 MHz, CD3OD) 8.12 (m, 1H, o-CH), 7.82 (m, 2H, m-CH), 7.45 
(tr, 1H, p-CH), 3.84 (br, 14H, NCH2), 3.78 (br, 6H, NH2CH2CH2), 3.65 (m, 36H, 
CH2OCH2), 3.22 (m, 6H, N-CH2), 3.04 (tr, 2H, NHCH2CH2S); 13C NMR (75 MHz, 
CD3OD) 166.1, 165.0, 164.4, 157.0, 150.0, 137.8, 121.1, 119.8, 71.2, 70.2, 43.5, 42.9, 
40.3. NMR Spectra are in Supporting Information. MALDI-TOF (m/z): [M + H]+ calcd 
for C48H82ClN21O9S2, 1196.6; found, 1196.6. 
Synthesis of 5. Dendrimer 4 (0.028 g, 0.013 mmol) was reacted with 85% 
trifluoroacetic acid (TFA, 1.5 mL) for 14 h (1:1 TFA:CH2Cl2). A yellow oil was obtained 
after solvent evaporation (0.025 g, 98.3 %). 1H NMR (300 MHz, CD3OD) 8.37 (m, 2H, 
o-CH), 7.77 (m, 4H, meta-CH), 7.16 (tr, 2H, p-CH), 3.68 (br, 24H, NCH2), 3.59 (m, 48H, 
CH2OCH2), 3.48 (tr, 2H, C(O)NHCH2CH2S), 3.21 (tr, 10H, NHCH2), 3.04 (tr, 2H, 
C(O)NHCH2CH2S), 1.41 (s, 27H, OC(CH3)3). 13C NMR (75 MHz, CD3OD) 171.2, 
166.2, 165.9, 161.6, 158.0, 149.8, 122.1, 120.9, 119.2, 80.1, 71.5, 71.2, 71.1 44.2, 41.3, 
36.2, 33.8, 31.9, 28.9. MALDI-TOF (m/z): [M + H]+ calcd for C75H122N24O16S4, 1743.7; 
found, 1743.7.  
ssDNA handling. Oligonucleotides can be custom-synthesized by various 
companies for different research demands, but two standard modifiers prevail as the most 
synthetically and economically feasible options: amino modifiers and thiol modifiers. 
The oligonucleotides can be modified on either the 5′ or 3′ terminus. For this work, both 
5′ and 3′ thiol-modified oligonucleotides were used to form disulfide linkages with 
various dendrimers. Oligonucleotides (0.1 OD/ µL) were deprotected on immobilized 
TCEP (2-carboxyethylphosphine) for 15 min at room temperature and eluted with two 
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volumes of TBE (45 mM tris(hydroxymethyl) aminomethane (Tris)-borate, 1 mM 
EDTA) pH 8.3 buffer. The use of other buffers including Tris buffer at pH 6.0 and 7.4, 
did not elute the DNA from the resin. 
ssDNA-dendrimer conjugation. The synthesis and characterization of all 
covalently-linked DNA-dendrimer conjugates was carried out in solution phase. Thiol-
terminated oligonucleotides were added to second- and third-generation triazine-based 
dendrimers via thiol/disulfide exchange chemistry as shown in Scheme 2-2. In a typical 
conjugation, deprotected ssDNA [2.5 OD, 25 µL H2O] was incubated with thiopyridyl-
containing dendrimer (41.8 nmol). After 12 h at room temperature the reaction was dried 
in vacuo, yielding the disulfide conjugated ssDNA-dendrimer. Scheme 2-2 shows the 
structure of the dendrimer used to make conjugates AI, AII, and BII. 
MALDI-TOF. An overlayer preparation was used with a 2,4,6-
trihydroxyacetophenone (THAP) matrix (22). A 1:1:1 mixture of 1 µM aqueous reaction 
mixture, 10 mg/mL THAP matrix in methanol, and 15 mg/mL aqueous ammonium citrate 
was spotted in 1 µL aliquots on a bed of THAP matrix. The analyte-doped matrix crystals 
were washed repeatedly (~5-15 times) with 5 µL of cold water to remove alkali metals. 
MALDI-TOF mass spectra were acquired in positive- and negative-ion mode on a 
Voyager-DE STR mass spectrometer (Applied Biosystems, Framingham, MA) equipped 
with a pulsed nitrogen laser emitting at 337 nm. Samples were analyzed in linear mode 
using a delayed extraction time of 550 ns and an accelerating voltage of 20 kV. The laser 
light intensity was adjusted to provide the optimal signal-to-noise ratio. All spectra were 
the result of signal averaging 50-100 laser shots. Positive-ion mass calibrations were 
performed internally with the [M + 2H]2+, [M + H]+, and [2M + H]+ ions of insulin 
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(bovine). Negative-ion calibrations were performed externally with the [M - H]- and the 
[2M - H]- ions of a standard single stranded 12-mer oligonucleotide. 
 
Scheme 2-2 
 
 
 
 
 
N
N
N
N
N
Cl
N
N
N
N
N
N
N
N
NH
NH
NH
HN S
O
O
O
O
O
O
O
O
O S
N
NH2
H2N
H2N
C48H82ClN21O9S2
Exact Mass: 1195.57
Mol. Wt.: 1196.89
S-S S-S Pyr HS + + 
S-S Pyr = 
S
HN
31 
Scheme 2-3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A1(a): 5′ G2 dendrimer-S-S-(CH2)6-TTTTTTTTTTTTTTTAGACTCTGACTCAGTG 3′ 
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Scheme 2-4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AI (b): 5′ G2 dendrimer-S-S-(CH2)6-TTTTTTTTTTTTTTTATGCTTCGATGCAACG 3′ 
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Scheme 2-5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AII: 5′ G2 dendrimer-S-S-(CH2)6-ATGCTCAACTCT 3′ 
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Scheme 2-6 
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AIII: [5′ Oregon Green-(CH2)6-TAGGACTTACGC-S-S-(CH2)3]2-G2 dendrimer 3′ 
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Scheme 2-7 
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BI: 5′ Oregon Green (CH2)6-TAGGACTTACGC-(CH2)3 -S-S-G3 dendrimer 3′ 
N
N
N
N
N
N
N
N
N
N
N N
N
N
N
N
N
N
HN
NH
NH
H
N O
O
OH2N
O
O O
H2N
O
O
O
H2N
OO
O
NH2
N
N
N
N
N
N
N
N
N
N
H
N
HN
HN
NH
O
O O
H2N
OO
O
NH2
O
O
O
NH2
O
O
O
H2N
N
N
N
N
N
N
N
O
S
O
F
F
OH
O
F
F
OHN
S
F
O
HO
O
NH
O
O
NO
O
O
P
O
HO O
NN
N
N
NH2
O
O
P
O
HO O
NHN
N
O
NH2
N
O
O
P
O
HO O
NHN
N
NH2N
O
O
P
O
HO O
O
O
P
O
HO O
NHN
N
O
NH2
N
O
O
P
O
HO O
NH
O
O
NOO
P
O
HO O
NH
O
O
NOO
P
O
HO O
NN
N
N
NH2
O
O
P
O
HO O
N
NH2
O
NOO
P
O
HO O
NHN
N
O
NH2
NO
O
P
O
HO O
N
NH2
O
N
O
O
P
O
O OH
N
N
NH2
O
P
OHO
S
C264H389F5N97O107P13S3
Exact Mass: 7223.37
Mol. Wt.: 7227.35
36 
Scheme 2-8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BII: 5′ Oregon Green [CH2]6-TAGGACTTACGC-[CH2]3 -S-S-G2 dendrimer 3′ 
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Scheme 2-9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BIII: 5′ TTTTTTTTTTCGCATTCAGGAT-(CH2)3 -S-S-G2 dansyl-dendrimer 3′ 
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Gel electrophoresis.  Polyacrylamide gels (20%) were run in TBE (90 mM Tris-
Borate, 2 mM EDTA) at 75 V for 2-3 hours using 0.25% bromophenol blue and 40% 
(w/v) sucrose in water as a sample buffer. Samples were prepared by adding 0.1 volume 
of sample buffer to each dendrimer and conjugate solution. Gels were soaked in ethidium 
bromide (4 µL per 100 mL running buffer) while gently rotating, for 20 minutes. After 
removing the excess ethidium bromide by incubating the gel for 2 minutes, 3 times, in 
running buffer, bands containing DNA were visualized on a UV transilluminator. The gel 
was stained with Coomassie Brilliant Blue R250 on a rotator for 1 hour, and destained in 
40% methanol, 10% acetic acid in water, until bands were clear. The destaining process 
sometimes took up to 12 hours to remove enough background to clearly see blue bands 
corresponding to dendrimer. Gels were visualized on a transilluminator, and all pictures 
were recorded on a CCD camera.  
HPLC purification.  A model 600 Waters HPLC workstation equipped with a 
model 2487 dual absorbance detector and XTerra MS C18 2.5 µm, 4.6X50 mm column 
was used for the purification of all DNA-dendrimers. An example of a typical solvent 
gradient is described for a 12-mer oligonucleotide attached via disulfide linkage to the 
periphery of a G2 dendrimer. Parameters must be optimized, however, for DNA-
dendrimers of differing sizes and charge ratios.  Buffer A, 100% acetonitrile, was 
increased from 0% to 50% with respect to Buffer B, 0.1 M TEAA pH 7.5 containing 15% 
acetonitrile, at a rate of 1 mL/min over 15 minutes. Samples were dried in vacuo, 
dissolved in 0.1 M TEAA pH 7.5 containing 15% acetonitrile to a final concentration of 
approximately 1 µg/µL, and loaded onto a 20 µL sample loop at about 20 µg per 
injection. Absorbance was monitored at wavelengths 254 and 260 nm. 
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RESULTS AND DISCUSSION 
 
Single-stranded DNA oligonucleotides were successfully attached to dendrimers 
at the core, the periphery, and both sites. To distinguish between covalent attachment and 
electrostatic association, conjugate AII from Scheme 2-5 was rigorously characterized 
using polyacrylamide gel electrophoresis (PAGE), high-performance liquid 
chromatography (HPLC), and matrix-assisted laser desorption ionization time-of-flight 
(MALDI-TOF) mass spectrometry. All other conjugates were analyzed by MALDI-TOF. 
Whenever sufficient material was available, further analysis was carried out by gel 
electrophoresis. 
Evidence for AI from MALDI-TOF.  Two different 5′ thiol modified 31-mer 
oligonucleotides were used to prepare AI-type conjugates. The reason for preparing two 
conjugates with the same molecular weight will become clear in Chapter III. Briefly, the 
conjugates contain the exact same nucleotide (G, C, A and T) content, but different 
sequences, in order to study their hybridization by surface plasmon resonance (SPR) 
analysis. Hybridization efficiencies increase with increased GC base pair content, so 
strands with the same GC base pair content were designed. Sequences used for AI 
conjugates were: 
 
5′ DMT-C6-S-S-C6-TTT TTT TTT TTT TTT AGA CTC TGA CTC AGT G 3′ 
and 
5′ DMT-C6-S-S-C6-TTT TTT TTT TTT TTT ATG CTT CGA TGC AAC G 3′  
40 
for 31-mer (a) and 31-mer (b), respectively. Conjugation of 31-mer (a) with G2 
dendrimer via disulfide bond formation afforded AI (a). Likewise, Conjugation of 31-
mer (b) with G2 dendrimer via disulfide bond formation afforded AI (b). The mass to 
charge ratio (m/z) for negative ion mode [M-H]- MALDI-TOF was calculated for 
conjugates A1 (a) and A1 (b) to be 10,725.01 and 10,724.79, respectively. The observed 
m/z for AI (a) and for AI (b) was 10,724.83 (Figures 2-1 and 2-2 respectively). Doubly 
charged species ([M-2H]2-) were also observed. The calculated [M-2H]2- AI (a) and AI 
(b) was 5362.51, and the observed signal was found at 5361.78 for AI (a) and 5361.72 
for AI (b) (Figures 2-1 and 2-2 respectively). Some unreacted oligonucleotide thiol 
remained in the sample after filtration. The (m/z) [M - H]- calculated for excess thiol was 
9639.29, and the observed signal was found at 9638.79 for the thiol corresponding to AI 
(a), and 9638.89 for the thiol corresponding to AI (b) (Figures 2-1 and 2-2 respectively).  
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Figure 2-2. MALDI-TOF spectrum corresponding to dendrimer-bound 31-mer, AI (b). 
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Figure 2-1. MALDI-TOF spectrum corresponding to dendrimer-bound 31-mer, A1 (a) 
42 
Evidence for AI from gel electrophoresis.  To verify covalency, conjugate AI 
(b) was visualized by polyacrylamide gel electrophoresis. Two lanes on the 20% 
polyacrylamide gel shown in Figure 2-3, compare free thiol oligonucleotide, in lane 1, 
with the dendrimer-bound conjugate AI (b), in lane 2. Ethidium bromide staining (gel A) 
allowed for the detection of oligonucleotide present in the sample, and a consequent 
coomassie stain (gel B) revealed the presence of dendrimer. The two bands present in 
lane 1 correspond to oligonucleotide disulfide formed during sample preparation, at the 
top, and the free thiol at the bottom. Lane 2 confirms the presence of the free thiol seen in 
AI (a) and AI (b) by MALDI-TOF, in the bottom lane, and the corresponding disulfide 
appears at the top, directly adjacent to the starting material shown in lane A. A third, faint 
band is observed in the middle of lane 2, corresponding to AI (b). A coomassie stain of 
the same gel, shown to the right, confirms the presence of dendrimer in lane 2, as only 
dendrimer will stain by coomassie.115 Accordingly, there were no bands observed in lane 
1. The faintness of the band corresponding to conjugate might be a result of photo-
quenching by the dendrimer. HPLC has proven to be the only effective method to remove 
all of the un-conjugated oligonucleotide, which as presented for AII has been 
successfully implemented. HPLC purification of AI (a) and AI (b), however, was not 
necessary for the non-quantitative, proof-of-concept comparison analysis presented for 
this work. 
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Figure 2-3. 20% polyacrylamide gel of AI (b) visualized by differential staining with (A) 
ethidium bromide and (B) Coomassie Brilliant Blue R-250. 
 
 
Evidence for AII from HPLC.  The oligonucleotide used in this work was: 12-
mer (HS-C6)5'-ATGCTCAACTCT-3'. For the 12-mer-G2 DNA-dendrimer (AII), three 
major peaks were observed at 254 nm with retention times of 6.4, 8.4, and 10.4 minutes, 
as shown in Figure 2-4. Peaks A, B, and C correspond to 12-mer thiol, 12-mer disulfide 
starting material (a result of both incomplete reduction to the thiol and reformation of the 
disulfide starting material by oxidation), and AII, respectively. Like peaks were pooled, 
concentrated on a rotory evaporator, and analyzed by non-denaturing 20% 
polyacrylamide gel electrophoresis (PAGE) and MALDI-TOF.  
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Figure 2-4. HPLC trace of crude AII reaction mixture after conjugation reaction. 
 
 
Evidence for AII from MALDI-TOF.  Figure 2-5 contains four separate 
MALDI spectra. The mass spectrum corresponding to the crude reaction material is 
compared to mass spectra corresponding to the three fractions (A, B, and C) pooled from 
eight separate HPLC injections (HPLC shown in Figure 2-4). The structure and 
molecular formula information for AII is shown in Scheme 2-1. The calculated MALDI-
TOF (m/z) [M+H]+ for AII was 4863.29, and the observed signal was 4863.12. The 
MALDI-TOF peak corresponding to the auto-oxidized disulfide ssDNA appears at 
7558.2. 
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Figure 2-5. MALDI-TOF spectra corresponding to AII crude reaction material (top) and 
purified fractions A, B, and C from HPLC (chromatogram shown in Figure 2-4). 
 
 
Evidence for AII from gel electrophoresis.  Polyacrylamide gels (20%) allowed 
successful separation of the initial G2-dendrimer, the ssDNA, and the DNA-dendrimer 
products as shown in Figure 2-6. Gel (A) was stained with ethidium bromide, which 
stains DNA but not the dendrimers used in this study, and gel (B) was stained with 
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coommassie brilliant blue R-250, which stains the dendrimer but not the DNA. Starting 
from the lowest band in Figure 2-6 A, lane 3, the three bands correspond to unreacted 
DNA-thiol, DNA-dendrimer conjugate, and a disulfide-coupled DNA dimer. The two 
bands present in lane 2 of Figure 2-6 A correspond to DNA-thiol (lowest band) and the 
anticipated DNA dimer (top band), which is produced by oxidation of two DNA-thiol 
oligonucleotides to a DNA-S-S-DNA disulfide. Lane 1 in Figure 2-6 A contains a DNA 
ladder (10-100 base pair). The lowest band in lane 2 corresponds to double stranded 12-
mer. Double-stranded DNA (dsDNA) is rigid and therefore is retarded on a 20% 
polyacrylamide gel while ssDNA migrates more efficiently through the dense matrix. 
Thus, the single stranded 24-mer (two disulfide linked 12-mers) shows up just below the 
double stranded 10-mer (which contains 20 bases). Removal of ethidium bromide, 
followed by staining with Coomassie Brilliant Blue R250 resulted in the gel shown in 
Figure 2-6 B. Only the middle band in lane 3, corresponding to the DNA-dendrimer, is 
visible. In contrast, all other bands corresponding solely to DNA are not stained. The 
absence of a band corresponding to the cationic dendrimer is attributed to the inability of 
these charged species to enter the polyacrylamide gel (they would migrate toward the 
cathode).  
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Figure 2-6.  20% polyacrylamide gel of AII visualized by differential staining with (A) 
ethidium bromide and (B) Coomassie Brilliant Blue R-250. 
 
 
Evidence for AIII from MALDI-TOF.  Disulfide exchange between the di-thio-
pyridyl G2 dendrimer with two Oregon Green labeled 12-mers did not proceed 
efficiently. Both disulfide formation between two 12-mers and re-oxidation of the 12-
mers with the C3 thiol modifier (protecting group) as supplied by Trilink were competing 
with formation of the desired product. Data from the crude reaction material is shown as 
proof that the construct can be prepared. Thiol-terminated DNA is present in the MALDI 
spectrum at m/z = 4474.1 (calculated m/z = 4474.0), and the corresponding doubly 
charged species appears at m/z = 2238.4 (calculated m/z = 2238.0). Reformation of the 
thiol-protected starting material through disulfide formation with the 3-
mercaptopropanol-modifier resulted in a peak at m/z = 4566.7 (calculated m/z = 4564.2). 
A peak corresponding to one ssDNA addition to the G2 dendrimer was observed at m/z = 
5807.4 (calculated m/z = 5800.8). 
S-S
S-S
HS
1        2         3    1         2          3
A B
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Figure 2-7. MALDI-TOF spectrum corresponding to crude AIII. 
 
 
Evidence for AIII from gel electrophoresis.  Crude reaction material from the 
conjugation of 2 equivalents of thiol-terminated 12 mer ssDNA with the dithiopyridyl 
dendrimer shown in Scheme 2-2, was run on a 20% polyacrylamide gel with 12-mer 
ssDNA post-reduction with TCEP. As shown in Figure 2-8, the thiol-terminated 12-mer 
and the auto-oxidized 12-mer disulfide were visible in lane 1 after ethidium bromide 
staining. In lane 2, a significant amount of starting material was present relative to the 
products corresponding to singly and doubly substituted dendrimer. As demonstrated for 
the AII conjugate, the conjugation reaction did not appear to go to completion owing 
most likely to the competing auto-oxidation reaction between thiol-terminated 12-mers. 
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The intensity of ethidium bromide staining for thiol- and disulfide- ssDNA relative to 
ssDNA-dendrimer is consistent with MALDI-TOF relative intensities. Poor yields 
precluded the ability to visualize the dendrimer by coomassie staining, which has a 
detection limit in the 0.5 µg range for large proteins vs. ethidium bromide which can 
detect as little as 1 ng plasmid DNA.116 
 
 
 
 
 
 
 
 
 
 
Figure 2-8. Ethidium bromide stained 20% Polyacrylamide gel of crude AIII. 
 
 
Evidence for BI from MALDI-TOF.  The 12-mer oligonucleotide sequence for 
BI formation was: (Oregon Green)5′-TAGGCGTTACGC-3′(C3-SH). A difference 
spectrum (Figure 2-9, C) was used to determine if low molecular weight signals were 
arising from the ssDNA, or if they were impurities from the conjugation reaction. A 
spectrum of purified oligonucleotide (Figure 2-9, B) was subtracted from the signals 
S-S S-S 
S-S 
S-S 
HS 
1 2
HS 
S-S 
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arising from the conjugate reaction material (Figure 2-9, A). Only signal corresponding to 
the formed DNA-dendrimer conjugates remained. The peak at 5560 arose from the 
presence of the G2 monochloride intermediate shown in Scheme 2-4. The [M + H]+ 
calculated for DNA-dendrimer BI was 7226.4, and signal was observed at 7227.3.  
 
 
Figure 2-9. MALDI-TOF spectra corresponding to BI, G3 dendrimer – 12-mer ssDNA. 
A corresponds to crude product, B corresponds to HPLC-purified ssDNA starting 
material, and C is the difference spectrum obtained by subtracting B from A. 
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Evidence for BI from gel electrophoresis.  Throughout the course of these 
studies, attempts to observe G3 dendrimer-ssDNA conjugates were never successful. 
Neither ethidium bromide nor coomassie staining ever revealed or suggested the presence 
of the conjugate, yet after extensive de-salting procedures, a G3-12-mer was in fact 
observed by MALDI-TOF (see MALI-TOF evidence for BI). It was suspected that either 
the dendrimer was too bulky to penetrate the polyacrylamide matrix, or the positively 
charged dendrimer would not travel toward the cathode, or both. To determine if the 
dendrimer-ssDNA conjugate was in fact trapped in the loading well, a gel was run 
according to the procedures outlined above, then left intact. That is, the glass plates 
sandwiching the gel were not removed, and the gel was visualized on a fluorescence 
macroscope, provided by Dr. Paul Cremer, Texas A&M University, Department of 
Chemistry. We conclude that Oregon-green labeled ssDNA 12-mer was trapped in the 
loading well. Unconjugated ssDNA, loaded in an adjacent well was not observed in the 
well. As shown in Figure 2-10, the outline of the well is evident as a result of the Oregon 
green fluorescence emission. Unconjugated ssDNA was observed as a band in the gel, 
consistent with MALDI data indicating incomplete conjugation. 
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Figure 2-10.  PAGE gel of BI prior to removal from glass plates showing that the 
fluorescently labeled DNA-dendrimer conjugate does not penetrate the gel. The band in 
the gel corresponds to unconjugated ssDNA. 
 
 
Evidence for BII from MALDI-TOF.  As indicated previously, there are two 
potential linking motifs for the DNA-dendrimers: electrostatic and covalent. The mass 
difference between these two adducts is only 2 Da. Nevertheless, it is possible to 
distinguish between the two theoretical products using accurate-mass MALDI-TOF 
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analysis. With bovine insulin as an internal calibrant (insulin mass to charge ratio (m/z) 
[M + H]+ = 5734.39), the measured [M + H]+ m/z of BII was 5561.97 (Figure 2-11 B). 
This compared with the expected [M + H]+ of 5561.76, corresponding to an error of only 
36 ppm. An electrostatic adduct ([M + H]+ = 5563.85) would have resulted in a much 
larger mass error of 200 ppm. When insulin was used as an external calibrant, that is it 
was not mixed with the sample being analyzed, [M + H]+ m/z of BII was observed at 
5561.62 (Figure 2-11 A).  
In addition to mass spectrometry, Ellman's test (for free thiol) was used to 
distinguish between covalent and electrostatic attachment of DNA to the dendrimers. 
Ellman's reagent oxidizes free thiols to mixed nitrobenzyl disulfides, which are easily 
identifiable by mass spectrometry. No Ellman's adduct was observed for BII. Addition of 
a reducing agent, TCEP, to BII led to the disappearance of MALDI-TOF signal 
corresponding to the ssDNA-dendrimer conjugate and disulfide modified ssDNA, as 
shown in Figure 2-12. The disappearance of both disulfides confirmed that the ssDNA 
was linked to the dendrimer via disulfide bond formation.   
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Scheme 2-10 
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Scheme 2-11 
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Evidence for BIII from MALDI-TOF.  Mass spectrometry data clearly indicates 
that the majority of the ssDNA remained unbound to the dendrimer, as both peaks 
corresponding to the approximate molecular weight of dendrimer and ssDNA are present 
in the spectrum. The broadness of the peaks indicates the saltiness of the sample. Each 
phosphate on the ssDNA backbone can accommodate a sodium or potassium ion, giving 
rise to the observed mass distribution. A comparison of theoretical and experimental 
MALDI values for AI through BIII is shown in Table 2-2. 
 
Figure 2-13. MALDI-TOF data indicating the presence of BIII, and demonstrating the 
effect of trace salt contamination on mass spectral data acquisition. 
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Table 2-2. Comparison of theoretical and experimental MALDI (m/z) values. 
 
 
 
 
 
 
 
 
 
 
AI 
AII 
AIII 
BII 
BIII 
BI 
Calculated (m/z) Found (m/z) 
4,863.3  4,863.1  
7,228.4  7,227.3  
g5,561.76  5,561.97  
10,161.2 10,171.1 
8,884.1 gg8,641 - 9,147 
* S-S 
S-S * 
S-S 
S-S 
S-S S-S 
S-S 10,725.0 10,724.8  
      g  Used internal and external mass calibration for greater accuracy. 
   gg  Product not subjected to stringent de-salting procedures, so a broad signal  
       corresponding to all possible sodium additions across the sugar-phosphate    
       backbone resulted.  
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CONCLUSIONS 
 
A synthetic route toward ssDNA-dendrimer constructs has been presented and the 
nature of their interaction has been unambiguously proven to be covalent rather than 
electrostatic. The motivation for using cationic dendrimers stems from both the high 
water solubility that these groups afford, and the opportunity for electrostatic binding 
with ssDNA, which may be useful for enhancing the rate of covalent bond formation 
between the two species.  
Successful bulk-phase DNA computing requires the synthesis of soluble DNA-
bearing macromolecules that display a certain number of ssDNA strands of designated 
sequences. The final construct must offer a means to easily manipulate the attached DNA 
sequences and allow for routine spectroscopic analysis. To this end we have synthesized 
dendrimers based on melamine to contain a specific number of fluorophores and a 
specific number of covalently bound DNA strands. 
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CHAPTER III 
 
THE DETECTION OF DNA HYBRIDIZATION OF DNA-DENDRIMER 
CONSTRUCTS ON SURFACES 
BACKGROUND 
 
DNA hybridization, or dsDNA formation, of DNA- dendrimer constructs was 
detected using three different surface analysis techniques: Fourier transform infrared 
external reflection spectroscopy (FTIR-ERS), fluorescence imaging, and surface plasmon 
resonance imaging (SPRi). FTIR/ERS data shows evidence for surface hybridization of 
disulfide-linked, dansyl-functionalized DNA-dendrimer constructs with surface-bound 
probe DNA. Fluorescence imaging of a patterned ssDNA surface, created using µ-contact 
printing, clearly shows that binding of these DNA-dendrimer conjugate occurs 
predominately in the regions containing covalently bound complementary probe ssDNA. 
Covalently attached dendrimers without fluorophore labels were shown to 
inherently increase the sensitivity of SPRi, which simultaneously detects changes in 
refractive index across an entire microarray. SPRi has been shown to effectively measure 
bioaffinity interactions including DNA hybridization without the use of expensive labels 
or radiological tags.117 Imaging experiments, unlike conventional SPR experiments 
however, are performed at a fixed angle of incidence resulting in decreased sensitivity. 
To compound matters, the concentration of biological targets such as DNA, proteins or 
antibodies often approaches the limits of detection using many surface analysis 
techniques including SPR.  
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Second generation dendrimers based on melamine are shown to enhance SPR 
signal by increasing the molecular mass of the covalently bound target DNA, resulting in 
a proportionate change in refractive index. Dendrimers based on melamine have several 
surface groups for oligonucleotide attachment so they possess the ability to further 
increase signal as a function of dendrimer size, or generation, and number of attached 
oligonucleotides.  
SPR allows for the analysis of weak interactions between unlabeled biomolecules, 
thus circumvents the need to work with expensive fluorescent or potentially harmful 
radiological labels. To date, the most commonly used methods for increasing the 
sensitivity of SPR measurements rely on secondary signal enhancement, meaning that the 
signal enhancement event follows the measured recognition event, in this case 
hybridization. The proposed method is inherently more accurate, because the source of 
SPR signal amplification is the molecule participating in the recognition event, ie. the 
DNA-dendrimer conjugate.  
Currently, the most popular form of secondary signal enhancement in SPR is 
based on the enzyme-linked immunosorbent assay (ELISA) system, or sandwich assay.118 
This method either measures or takes advantage of highly specific antigen-antibody 
interactions at the surface. Once an antibody, referred to as the primary antibody, is 
target-bound, it serves as the target for yet another antibody, termed the secondary 
antibody. In conventional ELISA, the secondary antibody is attached to an enzyme that 
converts a given substrate into a readily detectable chromagen. SPR eliminates the need 
to rely on chromagenic detection and the activity of highly pH and temperature sensitive 
enzymes, and instead measures the secondary antibody directly. Liposomes119 and latex 
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particles120 have been used in conjunction with the sandwich assay to further enhance 
SPR signal. With respect to surface bound oligonucleotides, the polymerase chain 
reaction (PCR)121 and rolling circle amplification (RCA)122 have gained the most 
attention as sources of signal enhancement, but PCR has its drawbacks in surface 
analysis. RCA became more popular for use in microarrays due to the ability to localize 
amplified DNA and thus prevent interactions among DNA strands that originated from 
different locations on the array. Again, by coupling DNA-dendrimer conjugates with SPR 
analysis, measurements can be made directly without the need to perform enzymatic 
reactions. Colloidal gold particles,123 nanoparticles,124 cationic latex125 and biotin-
streptavidin systems126 have also been used to enhance SPR signal, but like all of the 
other examples, these methods rely on a secondary event for signal enhancement.   
The ability to engineer a certain number of unique reactive sites on the periphery of the 
dendrimer offers a degree of control and flexibility that is unparalleled by other 
microarray-based, label-free detection strategies. 127 Branched oligonucleotides, or “DNA 
dendrimers” have been prepared with similar goals in mind, however, the labile nature of 
the proposed DNA-dendrimer disulfide linkages offer reversibility and the opportunity to 
attach bioaffinity targets other than DNA.128  
 
EXPERIMENTAL PROCEDURES 
 
Materials. Reagents for monolayer formation, 11-Amino-1-undecanethiol, 
hydrochloride (HSC11H22NH2, 98%, Dojindo Molecular Technologies, Inc.) and 11-
mercapto-1-undecanol (HSC11H22OH, 97%, Aldrich Chemical Co.) were used as 
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received. The lyophilized powders were dissolved in UV/UF purified (Barnstead) water 
[0.1 OD/µL]. Positive photoresist (AZP4620) and developer solution were obtained from 
the Clariant Co. (Somerville, NJ). Poly(dimethylsiloxane) (PDMS) elastomers were 
obtained from Dow Corning (Sylgard 184, Midland, MI).  Gold-coated substrates were 
prepared by electron-beam evaporation of 10 nm of Ti followed by 200 nm of Au onto 
Si(100) wafers (Lance Goddard Associates, Foster City, CA).  The wafers were 
subsequently diced into 2.6 cm x 1.3 cm pieces.  Before each experiment all wafers were 
cleaned in low-energy ozone cleaner for 10 min (Boekel Industries, Inc., model 135500). 
Synthesis of fluorescent ssDNA-dendrimer for FTIR and micropatterning.  
Synthesis of the dansylated second generation dendrimer (5) used in FTIR and 
fluorescence imaging experiments was discussed in Chapter II (Scheme 2-1). Subsequent 
characterization of the disulfide-linked ssDNA-dendrimer formed from disulfide 
exchange between a thiol-terminated 22-mer ssDNA and 5 was also presented in Chapter 
II (to yield conjugate BIII). The procedure outlined in Chapter II for reduction of 
disulfide modified ssDNA to form thiol-terminated ssDNA was improved upon for this 
work as detailed below for the synthesis of 31-mer conjugates. Figure 3-1 illustrates the 
effectiveness of the improved method by MALDI-TOF. Peaks are resolved indicating 
decreased salt content, and thiol-terminated ssDNA has been effectively separated from 
incompletely reduced ssDNA. 
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Figure 3-1. MALDI-TOF spectrum of 22-mer illustrating improved thiol deprotection 
and de-salting techniques.  
 
 
To prepare the conjugate, thiol terminated DNA was reacted with 1 eq. thiopyridyl 
functionalized dendrimer in 0.1 M TEAA pH 7, at room temperature for 12 hours. 
Separation of the conjugate from the unreacted oligonucleotide and dendrimer was 
accomplished by centrifugation of the sample for 2 hours on Microcon 10,000 MWCO 
spin filters (Millipore) at 6,500 RPM. The sample was desalted by adding ultrapure water 
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to the sample retained in the spin filter, equal to the volume of filtrate, once every 30 
minutes for 5 cycles. 
Surface attachment of ssDNA.  Surface attachment (and subsequent surface 
analysis) was performed by Dr. Sang-Keun Oh and instrumentation provided by Dr. 
Richard Crooks, Texas A&M University. Gold coated substrates were immersed in a 
mixed ethanolic solution of 1 mM amine- and hydroxy-terminated alkanethiols (9:1 
NH2(CH2)11SH : HO(CH2)11SH) for 24 hours. The substrates were removed and rinsed 
with ethanol and water, and dried with N2. The heterobifunctional crosslinker, 
sulfosuccinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SSMCC), was 
used to convert the amine terminated SAM to an SSMCC activated surface by immersing 
the substrates in a 1 mM SSMCC solution in 0.1 M TEA (pH 7.1) for 30 minutes. After 
rinsing the surface with DMF and water, 2 µL 1 mM thiol terminated ssDNA in 0.1 M 
TEA (pH 7.1) was spotted onto the SSMCC activated surface. The surface was covered 
with a cover glass in a humidity chamber for 6 hours. The DNA exposed surface was 
rinsed with water, soaked for 1 hour in 2X SSPE (20 mM NaH2PO4, 300 mM NaCl, 2 
mM EDTA), 0.2% (7 mM) SDS buffer to remove non-specifically adsorbed DNA, and 
thoroughly rinsed with water. Hybridization was performed by immersing the DNA 
modified substrates in a 2 µM solution of complementary ssDNA-dendrimer conjugate in 
2X SSPE buffer.  
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Scheme 3-1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Surface patterning of ssDNA.  PDMS stamps were made by casting the 
prepolymer components of Sylgard 184 on a photopolymer master made by 
photolithography. Patterned SAMS were prepared by microcontact printing (µCP) of a 2 
µM ethanolic solution of hexadecane thiol on a gold coated surface using 
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regions were prepared according to the method outlined above for ssDNA surface 
attachment.  
Characterization of patterned DNA surfaces.  FTIR-external reflection 
spectroscopy (FTIR) measurements were carried out using an FTS-6000 spectrometer 
(Bio-Rad, Cambridge, MA) equipped with a Harrick Scientific Seagull reflection 
accessory (Ossining, NY) and a liquid-N2-cooled, narrow-band MCT detector.  All 
spectra were obtained at 4 cm-1 resolution using p-polarized light at an 84° angle of 
incidence with respect to the Au substrate. Fluorescence images of the patterned DNA 
surfaces were acquired with a fluorescence microscope (Nikon Eclipse TE 300, Nicon 
Co., Tokyo, Japan) equipped with band-pass filters, a 100 W mercury lamp, and a 
charged-coupled device camera (Photometrics Ltd., Tucson, Arizona).  The patterned 
DNA surfaces were placed face down in a droplet of 2×SSPE buffer on a glass coverslip 
placed on the microscope stage, and the fluorescence images were collected. 
Synthesis of 31-mer ssDNA-dendrimer for SPRi. The 31-mer G2 ssDNA-
dendrimer constructs used for SPRi work were synthesized according to the method 
reported in Chapter II to yield AI (a) and AI (b). Oligonucleotide words W1 and W2 (W 
for words) were synthesized on an automated synthesizer in Robert Corn’s Lab at 
University of Wisconsin, Madison.  The 5′ thiol modified 31-mer oligonucleotides:  
 
5′ DMT- C6H12-S-S-C6H12-TTT TTT TTT TTT TTT AGA CTC TGA CTC AGT G 3′  
and 
    5′ DMT- C6H12-S-S- C6H12-TTT TTT TTT TTT TTT ATG CTT CGA TGC AAC G 3′  
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were synthesized by Trilink Biotechnologies on a 0.2 µmole scale. HPLC purified 
oligonucleotides were shipped as lyophilized powders and reconstituted just prior to use 
in ultrapure water at a concentration of 0.1 ODs/ µL. For products reported herein, the 5′ 
thiol modifier was removed by incubating 0.1 µmole oligonucleotide with immobilized 
TCEP (Pierce). The procedure outlined in Chapter II for DNA–dendrimer conjugation 
was improved upon for this work. Originally, this procedure yielded approximately 80 
nmoles thiol terminated oligonucleotide which was then incubated at room temperature 
with 1.25 eq. thiopyridyl functionalized dendrimer to yield the disulfide linked conjugate. 
An alternate improved method for reduction of thiol modified oligonucleotides was to 
dissolve the lyophilized oligonucleotides in 100 µL 0.1 M DTT, 0.1 M TEAA pH 7 for 
30 minutes at room temperature to yield the 5′ oligonucleotide thiol and the 
dimethoxytrityl (DMT) protected thiol modifier. The DMT protected thiol modifier was 
the cause of greatly reduced yields in prior syntheses, so it was removed from the 
oligonucleotide solution on a Poly Pak cartridge (Glen Research). The cartridge was 
equilibrated with 2 mL HPLC-grade acetonitrile followed by 2 mL 2M TEAA pH 7. The 
reduced oligonucleotide was diluted to 5 mL and loaded onto the cartridge. The cartridge 
was flushed with 3 mL 0.1 M TEAA pH 7, followed by 10 mL 5% acetonitrile in TEAA 
to remove the DTT. Oligonucleotides were eluted in 500 µL 50% acetonitrile in water, 
while DMT protected thiol modifier remained bound to the cartridge.  Mass spectrometry 
was able to demonstrate the improved efficiency of the DTT mediated thiol deprotection 
protocol relative to the previously employed deprotection on TCEP gel. There was no 
evidence of incompletely reduced 25-mer, and the DTT removal on the Poly-Pak 
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cartridge also accomplished significant desalting, greatly improving the peak resolution 
by MALDI-TOF.   
Surface Plasmon Resonance imaging (SPRi). Gold surfaces were patterned 
according to the methods used above for Surface Patterning of ssDNA and Surface 
Attachment of ssDNA. The instrumentation used for SPRi measurements is shown in 
Scheme 3-2, obtained with permission from authors, as published in Annual Reviews of 
Physical Chemistry, 2000, 51, 41-63 (Appendix B).  
 
Scheme 3-2 
 
 
 
 
 
 
 
 
 
 
 
 
Briefly, light from a collimated polychromatic source was passed through a polarizer and 
onto a prism/Au sample assembly at a specific angle of incidence (θ). The reflected light 
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then passed through a narrow-band interference filter and was detected with a CCD 
camera. An image of an oligonucleotide array onto which ssDNA-dendrimer conjugates 
C1 and C2 were bound is shown on the lower left in Scheme 3-2. 
 
RESULTS AND DISCUSSION 
 
FTIR.  Figure 3-2 shows the FTIR spectra corresponding to each modification 
step. Spectrum A corresponds to the product of SSMCC activation. The appearance of a 
peak at 1710 cm-1 arising from the in-phase stretch of the maleimide carbonyl groups 
confirms the presence of the thiol-reactive maleimide groups on the surface. 
Unfortunately, spectrum B does not differentiate the carbonyl groups in the previous step 
from the carbonyl groups on the nucleotide bases. Thus the success of the surface 
attachment of ssDNA was not determined at this time. However, addition of ssDNA-
dendrimer conjugate BIII (Chapter II) to the surface bound probe ssDNA resulted in a 
loss of signal at 1710 cm-1, indicating the absence of carbonyl functionality at the surface 
and an enhanced signal around 1100 cm-1 indicating the presence of carbon-oxygen single 
bonds corresponding to the peg groups along the periphery of the dendrimer. 
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Figure 3-2.  FTIR spectra showing: (A) the presence of maleimide carbonyl groups, (B) 
presumably the nucleotide carbonyl groups, which also give rise to a stretch ~1710 cm-1, 
and (C) the carbon-oxygen single bonds (1100 cm-1) arising from the PEG-functionalized 
dendrimer upon hybridization with ssDNA-dendrimer conjugate. 
 
 
 
Surface patterning. Fluorescence imaging of the resulting DNA surface clearly 
shows that binding of the ssDNA-dendrimer conjugate occurs predominantly in the 
regions that contain covalently bound, complementary ssDNA. In Figure 3-3, the light (or 
bright green) areas correspond to those areas containing the surface-bound probe ssDNA. 
The resulting bright square regions arise from the fluorescence signal corresponding to 
the ssDNA-dansyl-modified-dendrimer conjugate that has successfully base paired with 
surface-bound ssDNA. The dark regions correspond to areas that do not contain surface-
bound complementary ssDNA and thus do not retain fluorescent dendrimer. This 
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experiment indicates that the ssDNA surface attachment was successful and suggests that 
the ssDNA-dendrimer-modified surface might be useful for the development of 
functional DNA microarrays and templates for further fabrication of nanostructures.  
Subsequent wash-off experiments of these surfaces showed no reduction in the 
fluorescence intensity, further indicating that the nature of the interaction between the 
dendrimer and ssDNA is a covalent bond. 
 
 
 
 
 
Figure 3-3. Micropatterned surface showing preferential hybridization of dansyl 
containing ssDNA-dendrimer conjugate (BIII) to areas on the surface containing 
complementary surface bound ssDNA. 
 
Surface plasmon resonance. Since the thermodynamic stability of DNA is 
dependent upon the number of guanine-cytosine (G/C) base pairs, all oligonucleotides 
were designed to contain the same G/C content. Consequently, their masses are identical, 
and the masses of their complements and dendrimer-bound complements, referred to as 
C1 and C2 (C for complements) in this chapter (AI (a) and AI (b) in Chapter II), are 
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identical. Table 3-1 displays the oligonucleotide sequences for W1, W2, C1, and C2. 
MALDI characterization for these conjugates was discussed in Chapter II. 
 
Table 3-1. Sequence information for oligonucleotide words (W) and dendrimer-
bound complements (C). 
 
 
 
 
 
A surface array was constructed with two DNA strands, or words (W1 and W2) of the 
same molecular mass, but with different sequences. The pattern of immobilized DNA 
probes W1 and W2 is shown in Scheme 3-3 (A). A side view of the surface array is 
shown in (B). The side view after exposure to C2 is shown in (C), and after exposure to 
C1 is shown in (D). 
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SPRi revealed the hybridization of compliment C1 to the immobilized probe W1, 
but not to mismatch W2 resulting in the SPR image and linescan shown in Figure 3-4 
(A). Likewise, C2 hybridized specifically with W2 in the presence of W1, as shown in 
Figure 3-3 (B).  
 
Scheme 3-3. 
A 
B 
C 
D 
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Figure 3-4. SPR image and linescan of (A) C1 and (B) C2 hybridized to surface-bound 
complement words, W1 and W2 respectively.   
 
 
Hybridization of complementary ssDNA with no bound dendrimer revealed a 
similar SPR image, but required higher sample concentration to make up for decreased 
sensitivity. Thus, increasing the molecular mass of the target led to an enhanced SPR 
signal and significantly decreased the limit of detection. Although this work only reports 
SPR data for surface-bound DNA-DNA hybridization, the method could be used to detect 
DNA-RNA and DNA-protein interactions as well as many other biological interactions, 
as long as one molecule is amenable to dendrimer functionalization and the other to 
surface immobilization.  
A 
B 
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CONCLUSIONS 
 
DNA-dendrimer constructs have been successfully hybridized with ssDNA 
attached to a gold surface, indicating that the covalently attached dendrimer does not 
preclude duplex DNA formation. Furthermore, disulfide linked DNA-dendrimer 
conjugates were shown to increase the sensitivity of surface oligonucleotide hybridization 
using surface plasmon resonance, demonstrating their potential as signal enhancement 
techniques. Moreover, due to the homogenous nature of these constructs they are also 
amenable to solution phase analytical techniques like gel electrophoresis, mass 
spectrometry, and a variety of automated spectral techniques for rapid analysis. 
Homogeneous detection capabilities allow for the opportunity to conduct real-time 
spectral analysis of several interactions between DNA and various other biomolecules. 
The ability to successfully hybridize covalently linked DNA-dendrimer 
conjugates with surface-bound probe DNA is significant in two general aspects; it offers 
i) evidence that dendrimers based on melamine are suitable for applications that rely on 
DNA hybridization and could be greatly improved by the incorporation of a dendrimer 
and ii) a rapid, highly engineerable alternative to the many attempts that have been made 
to detect the interactions of surface bound biomolecules directly without using labels. 
Variations of the reported conjugates could be a versatile and cost effective addition to 
many nanofabrication techniques that rely on hybridization including the i) preparation of 
more effective biosensors, ii) self-assembly of more complicated nanostructures, iii) 
development of more powerful DNA-computation strategies, and even iv) construction of 
more robust gene therapy agents.  
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CHAPTER IV 
 
PREPARATION, CHARACTERIZATION, AND ENZYMATIC MANIPULATION OF 
NON-DISULFIDE LINKED DNA-DENDRIMER CONJUGATES 
 
BACKGROUND 
 
One of the many reasons for the predominant use of oligonucleotides in 
nanoconstruction is their ability to be easily manipulated by a host of different 
commercially available enzymes. Standard restriction endonuclease protocols typically 
require the addition of dithiothreitol (DTT), mercaptoethanol, or a similar reducing agent 
to the restriction cocktail. Since disulfide-mediated conjugation would be unstable under 
such experimental conditions, interest turned to non-disulfide-mediated conjugation 
chemistry.  
Two standard nucleases were used for this work: BAM HI (from Bacillus 
amyloliquefaciens H) restriction endonuclease and EXO III, a unidirectional exonuclease. 
Endonuclease digestion is sequence-specific, and targets only double-stranded DNA 
(dsDNA) leaving any ssDNA intact. Scheme 4-1 illustrates the BAM-HI endonuclease 
recognition sequence indicating the DNA sequence that must be present in order for 
cleavage to occur, and the specific bases in which cleavage takes place. The resulting two 
strands contain overhanging ends that are complementary to one another (“sticky ends”) 
so that in non-denaturing or “native” conditions (buffer, ~pH 7-8), the strands may 
remain base paired but contain “nicks” or breaks in the phosphodiester backbone where 
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the enzyme has cleaved. Denaturing gels containing urea and formamide must be used to 
verify endonuclease cleavage since nicked and intact oligonucleotides are 
indistinguishable on a native gel.  
 
Scheme 4-1 
 
 
 
 
 
Exonuclease III, on the other hand catalyzes the stepwise unidirectional cleavage of 
mononucleotides from the 3′ terminus (3′ overhangs of ≥ 4 bases are protected) of 
dsDNA yielding nucleoside 5′ phosphates (dA, dG, dT, and dC) and the remaining 
ssDNA (Scheme 4-2). Since the enzyme is specific for dsDNA, the complementary 
strand remains intact. 
 
Scheme 4-2 
 
 
Initially, a G3 dendrimer with a thiol-reactive maleimide functional group (Scheme 4-3 
A) at the core was attached to both 5′ thiol terminated 25-mers (a) and (b). Purification 
5'..G±GATCC..3' 
3'..CCTAG°G..5'  
BAM HI 
5'..GGATCC..3' 
3'..CCTAGG..5'  
EXO III                   5'..GGATCC..3'           
dC, dC,  dT, dA,       GG..5'   
5'..G   GATCC..3' 
3'..CCTAG   G..5'  
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and characterization by MALDI-TOF was successful, but consistent with previous 
attempts, the G3 dendrimer was too large to travel through polyacrylamide gels. Even 
gradient gels starting at 4% polyacrylamide, the loosest polyacrylamide matrix available, 
did not permit dendrimer migration. A smaller G1 maleimide (Scheme 4-3 B) was linked 
to 25-mer (a) in order to demonstrate that maleimide-crosslinked ssDNA-dendrimer 
conjugates do travel through polyacrylamide gels. The G1 construct was not large enough 
for ideal resolution on a polyacrylamide gel, and was decidedly too small for most DNA-
dendrimer applications which require a G2 dendrimer or larger. Therefore, further 
evaluation of hybridization and enzymatic manipulation relied on spectral studies of the 
G3 conjugates. 
 
Scheme 4-3 
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EXPERIMENTAL PROCEDURES 
 
Dendrimer synthesis. The monochloride G3 dendrimer (MW 3417) used to 
prepare the conjugates for this work was provided by Dr. Alona Umali. The purified 
monochloride (30 mg, 8.8 µmol) was reacted with 10 equivalents of piperazine (10 mg) 
in 1 mL THF at 50ºC overnight which afforded the crude piperazine-activated product. 
Excess piperazine was precipitated in 0.6 mL of 5:1 methanol: water and the soluble 
portion was filtered on a 0.22 µm spin filter (Millipore) and dried in vacuo. The resulting 
yellow oil was dissolved in 0.5 mL dichloromethane and extracted twice in water to yield 
the semi-purified piperazine activated G3 dendrimer in 69% yield (~20.8 mg). Just prior 
to DNA conjugation, the heterobifunctional crosslinker, N-(6-
maleimidocaproxy)succinimide (EMCS, 6.7 mg, 22 µmoles) was added (in 0.25 mL 
THF) dropwise from a syringe needle to the piperazine-activated G3 dendrimer (19.2 mg, 
5.5 µmoles) in a final volume of 0.5 mL THF. The reaction proceeded at room 
temperature for 1 hour and the sample was dried in vacuo. Excess linker was removed by 
solid-phase sequesteration of the excess NHS ester on piperazinomethyl polystyrene 
(slurry, 0.1 g in 0.4 mL acetonitrile) in a final volume of 0.8 mL. Linker sequesteration 
proceeded at room temperature for 20 minutes and the semi-purified dendrimer was 
removed in a 0.22 µm spin filter. Dendrimer was recovered from the beads in 65% yield 
(~13 mg).  
Thiol-terminated ssDNA preparation. Base-pair complementary thiol 
terminated 25-mer oligonucleotide sequences (25-mers (a) and (b) shown below) 
containing 5′ C6 thiol modifiers were purchased from Trilink Biotechnologies, Inc. 
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25-mer (a) - (HS-C6)5′-GGTTGGATATCTTTTTGGATCCTTC-3′ 
and 
25-mer (b) - (HS-C6)5′-GAAGGATCCAAAAAGATATCCAACC-3′ 
 
Polyacrylamide gel analysis and HPLC purification were also provided by Trilink. 
Approximately 40 OD’s 25-mer (~0.15 µmoles) ssDNA was dissolved in 100 µL 0.1 M 
dithiothreitol (DTT) in 0.1 M triethylamine acetate (TEAA) pH 8.32, vortexed for 10 
seconds and allowed to sit at room temperature for 30 minutes. An O-dimethoxy trityl 
(DMT)-on Poly-Pak cartridge (Glen Research) was prepared by flushing the cartridge 
with 2 mL acetonitrile followed by 2 mL triethylamine acetate (TEAA) pH 7.4. The 
sample was loaded at a rate of 1-2 drops per second then pushed through the cartridge a 
second time. The loaded cartridge was washed with 3 mL 1:20 ammonium hydroxide 
followed by 2 mL ultrapure water. The ssDNA was detritylated by washing the cartridge 
with 2 mL 2% trifloroacetic acid (TFA) then flushed with 2 mL ultrapure water. 
Oligonucleotide was eluted in 20% acetonitrile. The first 4 drops were collected in a 
microcentrifuge tube, and 6 drops per tube were collected for the next 3 fractions. 
Usually the detritylated thiol terminated DNA was eluted in the 2nd and 3rd fractions as 
determined by UV-vis measurements at 260 nm (Chart 4-1). 
 
 
 
 
83 
Chart 4-1 
 
 
Linker-mediated conjugation. Thiol terminated ssDNA eluted from the Poly-
Pak was dried in vacuo, reconstituted in 50 µL water, and added dropwise from a syringe 
to a solution of EMCS-activated G3 dendrimer (0.2 µmoles) in 1 mL acetonitrile 
containing 10% diisopropylethylamine (DIPEA). The reaction proceeded at room 
temperature over 1 hour and was dried to a pellet in vacuo. Excess ssDNA starting 
material was removed on (mercaptomethyl)polystyrene (Sigma product number 63767) 
in 100 µL acetonitrile for 2 hours. Beads were removed from the soluble conjugate on a 
0.22 µm spin filter.  
It was necessary to deprotect the boc-protected amine periphery in order to afford 
water solubility for enzymatic reactions. Since partial boc-deprotection was observed 
after detritylation in 2% TFA on the Poly-Pak column, a dilute solution of TFA in 
acetonitrile (~5%) was used to remove the boc groups without degrading the ssDNA. 
After 1 hour at room temperature the TFA mixture was added to a 10,000 MWCO spin 
Poly-Pak Elution Profile
0
0.02
0.04
0.06
0.08
0.1
0.12
0.14
1 2 3 4 5
Fraction
A260
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filter and spun at 14,000 X g for 45 minutes. Filtrate was removed and 50 µL ultrapure 
water was added to the retentate. The sample was spun for 30 minutes at a time, 5 times, 
with the addition of 50 µL water between spin intervals to accomplish both desalting and 
separation from any remaining low molecular weight impurities. 
It was not possible to visualize the G3 crosslinked conjugates by gel 
electrophoresis. Therefore smaller constructs were prepared with the goal to demonstrate 
enzymatic manipulation of covalently-linked conjugates by gel electrophoresis. A G1 
dendrimer with a maleimide functionalized arm, provided by Dr. Hui-Ting Chen, was 
used as proof of concept that a covalently crosslinked ssDNA-dendrimer conjugate could 
be observed by gel electrophoresis. The GMBS linker used for this work differed from 
the EMCS linker from the previous construct by one less methylene in the hydrocarbon 
chain. The same protocol for formation of a covalent linkage between a thiol-terminated 
ssDNA and a maleimide activated dendrimer was used. 
Quantification. It is difficult to accurately quantify ≤ 2 mg product, but there are 
two different spectophotometric methods that are often employed to approximate ssDNA 
yield from oligonucleotide syntheses. For this work, matters are complicated by the 
significant overlap between the UV-vis absorption spectrum of ssDNA (λmax = 260) and 
that of the triazine-based dendrimers (λmax = 254) used for conjugation. Thus the yield 
calculated using the first approximation (EQN 4), which does not take into account the 
presence of the dendrimer, could be an under-approximation since some unknown 
amount of absorption was actually due to the dendrimer. Indeed a background reference 
containing only dendrimer could be used to solve this problem if the concentration of 
dendrimer in the sample was known. The second method for approximating ssDNA yield 
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takes into account the number of bases in the ssDNA and can therefore be tailored to 
contain more “bases” than are actually present. This method was employed for 
comparison.  
A 10 µL aliquot of ssDNA-dendrimer conjugate was diluted by a factor of 90 to 
yield 1 mL final volume for absorbance readings. The absorbance at 260, for a 90X 
dilution of ssDNA-dendrimer product was 1.11 (OD = 1.11, where OD = optical density). 
The conversion factor (cf) for calculations was 50, because 1/50th of the sample was used 
to measure absorbance at 260 nm (A260).  
The first approximation states that 1 OD (A260 = 1) equals 32 µg ssDNA (EQN 4-
1a). Taking the cf into consideration, as shown in EQN 4-1b, this approximation results a 
value of 1.78 mg for product yield (EQN 4-1c). 
 
1 OD = 32 µg DNA                    (EQN 4-1a) 
 
(measured A260) X (cf) X (0.032 mg) = yield (mg)                             (EQN 4-1b) 
 
(1.11) X (50) X (0.032 mg) = 1.78 mg                                                (EQN 4-1c) 
  
A second rule for quantifying ssDNA yield states that 1 µmol ssDNA is equal to 10 OD 
multiplied by the number of oligonucleotide bases (EQN 4-2a). The absorption properties 
of G2 dendrimers based on melamine are similar enough to that of nucleotide bases that 
the ε260 values are on the same order of magnitude. With that in mind, it was possible to 
count the dendrimer as an additional base in the 25-mer to make the total number of bases 
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to equal 26 (EQN 4-2b). Applying the second approximation resulted in a value of 2.28 
mg for product yield (EQN 4-2c). The values obtained from the two approximations are 
comparable enough with one another to estimate that approximately 2 mg EMCS-linked 
ssDNA-dendrimer was obtained using the synthetic procedures outlined above. 
 
1 µmole ssDNA = (10 OD) X (# bases) = 260 OD                         (EQN 4-2a) 
 
(55.5 OD X 1 µmole) ÷ 260 OD = 0.213 µmole                             (EQN 4-2b) 
 
(10,700 mg/ mmol) X (0.213 X 10-3 mmole) = 2.28 mg                 (EQN 4-2c) 
 
Hybridization. All buffer salts were purchased from EM sciences. Hybridization 
buffer (0.16 M KCl, 0.02 M Na2HPO4, 1 mM EDTA pH 7.5) was prepared with 
Barnstead ultrapure water and filtered through a 0.2 um spin filter just prior to use. 
Double stranded (ds) oligonucleotides were prepared by mixing a 1:1 ratio (16 µg, 2 
nmoles) of complementary ssDNA 25-mer (a) and 25-mer (b) at a final concentration of 
0.4 mM (5 µL) in hybridization buffer. Samples were kept at 37 ºC overnight then stored 
at 4 °C.  To prepare dendrimer-bound dsDNA, a 10-fold molar excess of 25-mer (a) or 
(b) ssDNA-dendrimer conjugate (16.7 nmol) was added to the corresponding 
complementary ssDNA (1.7 nmol) in 50 µL hybridization buffer. Samples were kept at 
37 ºC overnight then stored at 4°C.   
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UV-vis spectral comparisons. Nucleotide base stacking between complementary 
strands in dsDNA results in a decrease in UV absorption compared to ssDNA. This 
phenomenon is referred to as the hyperchromic effect. Due to this effect, the molar 
absorptivity for bases in dsDNA compared to that of ssDNA increases to 6.6 X 103. For 
all spectral measurements, the total concentration of DNA was diluted to ~30 ng/ µL in 
2X hybridization buffer.  
Melting point determination. The hyperchromic effect is used in a simple way 
to study the melting of duplex DNA. Increasing the temperature of the sample denatures 
the strands resulting in an absorption increase as the strands begin to exhibit ssDNA 
behavior. The melting temperature (Tm) can be determined experimentally by heating the 
duplex DNA while recording A260 measurements and plotting temperature vs. 
absorbance. The Tm is determined by calculating the temperature at which half of the 
maximal absorption has occurred, or in other words, the temperature at which 50% of a 
given oligonucleotide is hybridized to its complementary strand. In the absence of 
destabilizing agents, like formamide or urea, Tm will depend on 3 major parameters: 
1. The sequence: a GC-rich sequence has a higher melting temperature.129  
2. The strand concentration: high oligonucleotide concentrations favor hybrid 
formation, which results in a higher melting temperature.130 
3. The salt concentration: high ionic strength results in a higher Tm as cations 
stabilize the DNA duplexes.131 
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For oligonucleotides greater than 15 bases long, there is a simple calculation to 
approximate the melting temperature: 
 
          Tm (°C) = 81.5 + 16.6 log M + 41(XG + XC) - 500/ L - 0.62F                 (EQN 4-3) 
Where: 
M = molar concentration of monovalent cations 
XG and XC = mole fractions of G and C in the oligonucleotide  
L = length of the shortest strand in the duplex  
F = molar concentration of formamide 
 
Solving for M = 0.4 (hybridization buffer contributed ~0.4 M [Na+] and [K+] after drying 
the sample and re-dissolving it in fresh buffer), XG + XC = 0.4, L = 25, and F = 0: 
Tm = 81.5 + 16.6 (log 0.4) + 41 (0.4) - 500/ 25 - 0.62 (0) = 71.3 °C 
Enzymatic manipulation. Restriction digests were prepared according to the 
standard procedure supplied by Promega for Bam HI and Exo III enzymes. Three enzyme 
concentrations were tested for optimal digestion conditions. All digest mixtures were 
incubated at 37°C for 4 hours unless otherwise noted. Scheme 4-4 depicts the BAM HI 
digestion of thiol-terminated dsDNA. 
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Scheme 4-4 
 
 
MALDI-TOF. For MALDI-TOF, aqueous sample solutions (1µM) were mixed 
with the 2,4,6-trihydroxyacetophenone (THAP) matrix (15 mg/ml in acetonitrile) and 
aqueous ammonium citrate (15 mg/ml)  at a ratio of 1:1:1 prior to the application of 1 µL 
aliquots on a bed of THAP matrix.132  The analyte-doped matrix crystals were washed 10 
times with 5 µL of cold water to remove sodium and potassium ions.  An Applied 
Biosystems (Framingham, MA) Voyager-DE STR mass spectrometer operating in 
positive- and negative-ion mode was used to obtain the mass spectra.  The system is 
equipped with a N2 laser providing 337 nm, 3 ns wide pulses with the accelerating 
voltage maintained at 25 kV for this study.  Delayed extraction (~ 600 ns) mode was 
applied in linear time-of-flight detection.   
Denaturing gel electrophoresis. All gels were run on a Mini-Protean 3 Cell gel 
running apparatus from Bio-Rad. 5X Tris-borate EDTA (TBE) buffer pH 8.3 and DNA 
loading buffer were purchased from eppendorf. For denaturing conditions, 19% 
(HS-C6H12)5′-GGTTGGATATCTTTTTGGATCCTTC
CCAACCTATAGAAAAACCTAGGAAG-5′( C6H12-SH) 
±
°
(HS- C6H12)5′-GGTTGGATATCTTTTTGGAT CCTTC 
TAGGAAG-5′(C6H12-SH) CCAACCTATAGAAAAAC
BAM HI 
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polyacrylamide gels were prepared by adding 3.15 g urea to 3.75 mL 40% bis-acrylamide 
stock (BioRad) and 1.5 mL 5X TBE. Mild heating (60°C) and agitation was required to 
dissolve the urea. Just prior to pouring, 45 µL 10% ammonium persulfate (APS) and 3.5 
µL TEMED were added. All gels were run in 1X TBE, 80 V, 120 minutes. Samples were 
prepared by adding 1 µL DNA loading buffer (Eppendorf) and 1 µL formamide per 10 
µL sample in 1X TBE. The gel was run for 30 minutes at 80 V prior to loading as a 
means to remove any excess acrylamide or polymerizing agents from the loading wells, 
and just prior to loading, wells were cleared out with a 20 µL pipet. These steps proved 
very helpful in preventing the streaking of bands in the gel.  
Non-denaturing (native) gel electrophoresis. All 20% polyacrylamide gels were 
prepared by mixing 6.7 mL 40% bis-acrylamide stock (BioRad), 1.3 mL ultrapure water, 
and 2.0 mL 5X TBE. Just prior to pouring, 45 µL 10% ammonium persulfate (APS) and 
3.5 µL TEMED were added. Gels were run in 1X TBE, 80 V, 120 minutes. Samples were 
prepared by adding 1 µL DNA loading buffer (Eppendorf) per 10 µL sample in 1X TBE. 
As before, all wells were cleared of excess acrylamide and the gel was pre-run for 30 
minutes at 80 V. 
 
RESULTS AND DISCUSSION 
 
Purification. The ssDNA-dendrimer conjugated products were larger than 10,000 
Da, therefore their purification by spin filtration was greatly simplified. Experience has 
shown that while most low molecular weight impurities are retained on 3,000 molecular 
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weight cutoff (MWCO) spin filters (Millipore), 10,000 MWCO spin filters are more 
effective at separating larger dendrimers from low molecular weight impurities.  
MALDI-TOF. Mass spectrometry indicates the significant improvement in 
product isolation using the 10,000 MWCO spin filters. As shown in Figures 4-1 and 4-2, 
all unbound ssDNA was removed. Only signal corresponding to EMCS-linked ssDNA-
dendrimer conjugates remained. Figure 4-1 shows the MALDI-TOF spectrum 
corresponding to EMCS crosslinked construct containing 25-mer (a) and the structure 
and formula corresponding to this construct is shown in Scheme 4-5. Likewise, Figure 4-
2 shows the MALDI-TOF spectrum corresponding to EMCS crosslinked construct 
containing 25-mer (b) and the structure and formula corresponding to this construct is 
shown in Scheme 4-6. 
.  
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Figure 4-1. MALDI-TOF spectrum corresponding to EMCS crosslinked construct 
containing 25-mer (a). 
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Scheme 4-5 
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Figure 4-2. MALDI-TOF spectrum corresponding to EMCS crosslinked construct 
containing 25-mer (b). 
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Scheme 4-6 
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Gel electrophoresis (evidence of GMBS-linked conjugate). A characteristic 
band pattern for thiol terminated DNA and DNA-dendrimer conjugate was observed 
upon staining with ethidium bromide. The G1 dendrimer, however, was smaller than the 
previously observed G2 dendrimer, so it traveled lower on the gel, closer to the thiol 
terminated ssDNA. An image from the charge coupled device (CCD) camera (Figure 4-3) 
shows poor separation between the three bands in lanes 2 and 3. Lane 1 contains ~0.5 µg 
thiol terminated ssDNA, with the top band corresponding to the disulfide, and the lower 
band to the free thiol. Lanes 2 and 3 contain 2 different concentrations (1µg/ µL in lane 2, 
and 2µg/ µL in lane 2) of the same GMBS conjugated DNA-dendrimer sample. Both 
overloading (lane 3) and smearing (lanes 2 and 3) made these gels very difficult to 
analyze. Attempts to coomassie stain the dendrimer proved unsuccessful also likely due 
to the small size of the dendrimer resulting in an inability to retain the dye.   
 
 
 
Figure 4-3. Ethidium bromide stained 20% polyacrylamide TBE gel of a G1 dendrimer 
crosslinked to thiol-terminated ssDNA with GMBS.  
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UV-vis spectral comparisons. The hyperchromic effect is readily observed when 
comparing the UV-vis spectrum of ssDNA to that of dsDNA, a distinct decrease in 
absorbance at 260 nm is observed upon addition of 1 equivalent of complementary 
ssDNA. Much flatter spectra are observed for both dendrimer-conjugated ssDNA and 
dsDNA, indicating the presence of base stacking of ssDNA-dendrimer conjugates relative 
to that of ssDNA. When complement ssDNA is added to the conjugate, absorbance at 260 
nm slightly decreases indicating a small increase in the ordering or base stacking of the 
DNA. Based on these results alone, it is not possible to conclude that hybridization is or 
is not occurring between the complementary DNA strands, but is suggestive of an 
interaction between the ssDNA and dendrimer that results in a more ordered arrangement 
of bases on the DNA strand. Such an interaction could account for the inability of 
ssDNA-dendrimers to migrate through polyacrylamide gels partly due to the formation of 
a densely packed, globular structure, and partly due to charge neutralization affected by 
the terminal amine groups of the G3 dendrimer. 
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Chart 4-2 
 
 
Melting temperature comparison. The experimentally determined melting 
temperature (Tm) was very close to the calculated value (71.3 °C) discussed in EQN 4-3. 
The dendrimer has an obvious impact on the hyperchromic effect, but interestingly does 
not seem to prevent hybridization from taking place as determined by surface 
hybridization studies discussed in Chapter III. Melting curves show that disrupting any 
hybridization that could be occurring between the DNA strands does not give rise to a 
characteristic hyperchromic effect. Some ordered arrangement of DNA bases still exists 
at high temperatures giving rise to a much lower absorbance than would be expected for 
ssDNA. Nonetheless, addition of one equivalent of ssDNA to form the dsDNA-
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dendrimer conjugate results in a decrease in absorbance rather than an increase, as shown 
in Chart 4-2, indicating that a hyperchromic effect is observed in DNA-dendrimer 
systems. Indeed it appears that the curve corresponding to DNA-dendrimer conjugate in 
Chart 4-3 would continue to increase in A260 if heated above 85 °C, but temperatures 
exceeding 90 °C were beyond experimental capabilities. Experiments with dendrimer 
alone showed no increase in A260 upon sample heating. Since interactions between DNA 
and dendrimer versus DNA with DNA cannot be distinguished from one another using 
the hyperchromic effect, this method was not as helpful in discerning the extent of DNA 
hybridization as were the solid-phase hybridization studies in Chapter III. 
 
Chart 4-3 
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Comparison of Melting Curves 
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Enzymatic digestions. BAM HI endonuclease digestions were performed 
according to Scheme 4-7 A, and Exo III digestions according to Scheme 4-7 B. Each 
species has been assigned a number that corresponds with the numeric labels on the 
polyacrylamide gel studies that follow. The first column in Scheme 4-8 A corresponds to 
the hybridization of ssDNA strands 25-mer (a) and 25-mer (b) to form 2 with subsequent 
endonuclease digestion by BAM HI to yield 3. This first column was used as a control to 
compare the hybridization and enzymatic cleavage of the dsDNA-dendrimer conjugates. 
The second column shows the hybridization of ss25-mer (b), to the dendrimer-bound 25-
mer (a) conjugate 4, to form 5 with subsequent digestion by BAM HI to form 6. The third 
column shows the hybridization of ss25-mer (a) to the dendrimer-bound 25-mer (b) 
conjugate 7 and subsequent enzymatic cleavage by BAM HI to yield 8. The difference 
between the second and third columns arises from which of the two 25-mers (a or b) was 
covalently attached to the dendrimer. Scheme 4-7 B shows the Exo III digestion of ds25-
mer 2 and dsDNA-dendrimers 5 and 8 from Scheme 4-7 A, to form 10, 11, and 12, 
respectively. 
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Denaturing gel electrophoresis (evidence for BAM HI digestion). The 
ethidium-bromide stained 19% denaturing polyacrylamide gel is shown in Figure 4-4. 
The first two lanes contain single-stranded DNA (1) and dsDNA (2) resulting from the 
hybridization of 25-mer (a) with 25-mer (b). No band corresponding to hybridized DNA, 
which would lie higher on the gel, was observed in lane 2, revealing that the denaturing 
Scheme 4-7 
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conditions successfully separated dsDNA. BAM HI successfully cleaves the dsDNA (3) 
presumably yielding two large strands and two small strands that show up on the gel as 
two distinct bands. Conjugates (conjugate 4 from Scheme 4-7 A is shown) do not 
penetrate the gel. Hybridization with complement ssDNA to yield 6 results in a band 
corresponding to ssDNA, as expected under denaturing conditions. BAM HI cleavage 
occurs with 5 revealing the same pattern shown for digested dsDNA (3). The BAM HI 
digest of conjugate 4 reveals the same band pattern. BAM HI is specific for dsDNA. So 
although a denaturing gel cannot indicate successful hybridization, the DNA-dendrimer 
and ssDNA must have hybridized (or annealed) in order for enzymatic digestion to have 
taken place. Thus, at least partial hybridization occurs in the presence of dendrimer. A 
coomassie stain confirms that no dendrimer is present in the gel, consistent with ethidium 
bromide results indicating that G3 dendrimer-bound ssDNA does not penetrate the 
polyacrylamide matrix. The fact that no free ssDNA is observed in lane 4, corresponding 
to the covalent ssDNA-dendrimer conjugate allows us to confirm that the DNA present in 
lanes 5, 6, and 9 are not artifacts of excess unconjugated ssDNA. All experiments were 
performed using the same ssDNA-dendrimer stock solution, which according to gel 
electrophoresis is free of any unconjugated ssDNA. 
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Figure 4-4. Ethidium bromide stained 19% denaturing polyacrylamide gel of ssDNA 1, 
dsDNA 2, BAM HI digested dsDNA 3, ssDNA-dendrimer 4, dsDNA-dendrimer 5, and 
BAM HI digestions of two different dsDNA-dendrimers (4 and 7) to yield 6 and 9. 
 
 
Denaturing gel electrophoresis (evidence for Exo III digestion).  Another 
ethidium-bromide stained 19% denaturing polyacrylamide gel, this one illustrating the 
success of EXO III cleavage, is shown in Figure 4-5. The same band patterns for 2, 4, 5, 
and 8 were observed in this denaturing gel. EXO III digestion of dsDNA yields no bands, 
as presumably the free nucleotides run off the bottom of the gel during electrophoresis. 
The same is observed for dsDNA-dendrimer. Two exonuclease cleavage times are shown 
for 11. The first lane corresponds to a 1 hour digestion, and the 2nd to a 12 hour digestion 
1      2       3      4      5                6                9 
1       2      3        4        5                 6                9  
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indicating that the cleavage of dendrimer bound dsDNA requires more time than cleavage 
of dsDNA (for 10, reaction time = 1 hour).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-5. Ethidium-bromide stained 19% denaturing polyacrylamide gel of dsDNA 2, 
ssDNA-dendrimer 4, Exo III digestion of ds DNA 10, dsDNA-dendrimer 5, Exo III 
digested dsDNA-dendrimer 11 at reaction times = 1 hour and 12 hours shown fron left to 
right, and dsDNA-dendrimer conjugate 8. 
 
 
Non-denaturing gel electrophoresis The results from 19% non-denaturing 
polyacrylamide gel electrophoresis are shown in Figure 4-6. This gel provides evidence 
of base-pairing for BAM HI endonuclease digested dsDNA 6 that could not be detected 
2         4                  10           5     11    11 8
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in denaturing conditions. Exo III digestion does not allow base pairing of the cleavage 
products, so base pairing is not observed for the ssDNA-dendrimer Exo III digestion in 
lane 11. Incomplete digestion is however observed, as it was on the denaturing gels if the 
digestion was not allowed to proceed over ~12 hours. Again, ssDNA-dendrimer 4 did not 
enter the gel, but addition of complement allowed for visualization of mostly ssDNA. 
Comparing ethidium bromide intensities between dsDNA 2 and dsDNA-dendrimer 
conjugate 5, it appears that a small amount of 5 is base paired.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-6. 19% non-denaturing polyacrylamide gel of dsDNA 2, ssDNA-dendrimer 4, 
dsDNA-dendrimer 5, Exo III cleaved dsDNA-dendrimer 11, and BAM HI cleaved 
dsDNA-dendrimer 6. 
 
2                4                        5                 11  6
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CONCLUSIONS 
 
DNA cleavage is particularly useful for creating dynamic nanostructures and 
many surface-based techniques such as DNA-based computation, rely on the ability to 
strategically synthesis (“program”) DNA to contain specific cleavage sites for the 
removal of target DNA or the excision of DNA strands of predetermined length.  
New ways to exhibit control over DNA-dendrimer nanostructures through the use 
of dozens of commercially available, sequence-selective enzymes are just beginning to be 
explored. The ability of enzymes to function in the presence of covalently-linked 
dendrimers based on melamine, as demonstrated here, is hopeful as it suggests that the 
analysis of enzyme-substrate interactions and assays for sequence specificity using these 
constructs as scaffolds will be possible. 
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CHAPTER V 
 
SYNTHESIS OF MEGAMERS: MULTIVALENT STREPTAVIDIN-BASED 
PEPTIDE-DENDRIMER BIOCONJUGATES FOR TARGETED DRUG DELIVERY 
 
BACKGROUND 
 
An efficient synthetic strategy is proposed herein for the synthesis and 
characterization of macromolecules that exceed the threshold for EPR while displaying 
multiple end groups for manipulation using protein-ligand interactions.  This work 
demonstrates that biotinylated TAT peptide-dendrimer conjugates can assemble in the 
presence of streptavidin, a 60 kDa tetramer that binds 4 biotin molecules with a 
remarkably high association constant of 1014 M-1.133 Scheme 5-1 illustrates the assembly 
of 4 peptide-dendrimers around a streptavidin core to form a multi-dendrimer unit, or 
megamer. The chemical synthesis of the building blocks is straightforward,134 and 
noncovalent assembly occurs spontaneously.  Streptavidin has been used extensively to 
carry biotinylated molecules in vivo, most notably to increase the delivery of radioactivity 
to tumor tissue.135 The biotin-streptavidin interaction is stable in a wide range of 
temperatures, pH, organic solvents, and in the presence of sodium dodecyl sulfate (SDS) 
and urea. 
TAT is an arginine-rich protein transduction domain from HIV-1 that facilitates 
cell surface recognition, aids in transport across the membrane, and protects the 
transferred material from lysosomal degradation.136 TAT has been used to transfer 
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antibodies, polymers with and without drug bound, and a wide range of proteins.137-139  
The TAT sequence was synthesized on-bead, and a G2 monochloride dendrimer was 
attached as the terminal “residue” using the conjugation protocol discussed below.     
 
Scheme 5-1 
 
 
 
 
 
 
 
 
 
 
 
 
 
The characterization of megamers relied on sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE), matrix-assisted laser desorption 
ionization (MALDI) mass spectrometry, and spectral titrations using the HABA 
method.133 
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EXPERIMENTAL PROCEDURES 
 
Solid phase peptide synthesis (SPPS) materials.  Coupling agents: 
Benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBop) and N-
hydroxybenzotriazole (HOBT) were purchased from NovaBiochem along with fluorenyl 
methoxy carbonyl (Fmoc) protected amino acids: Glycine (Fmoc-Gly-OH), tert-butoxy 
carbonyl (boc)-protected L-lysine (Fmoc-Lys(boc)OH), 2,2,4,6,7-
pentamethyldihydrobenzofuran-5-sulfonyl (pbf)- protected L-arginine (Fmoc-Arg(pbf)-
OH), and trityl-protected L-glutamine (Fmoc-Gln(trt)-OH). Fmoc-protected 4-
carboxypiperidine (isonipecotic acid, Inp) and Fmoc-Lys(biotin)-wang resin were 
purchased from Advanced Chemtech. HPLC grade N,N-dimethylformamide (DMF) was 
used for all deprotection and coupling reactions. 
SPPS.  Peptide were synthesized on a 0.25 mmol scale by manual Fmoc solid 
phase peptide synthesis on Fmoc-Lys(biotin)-wang resin. Fmoc deprotection of the resin 
and all subsequent Fmoc deprotections were carried out in 4:1 DMF: piperidine in 10 mL 
final volume for 3 minutes and repeated 2 times. Beads were washed several times with 
dichloromethane then 2 times with DMF after each step. Amino acid coupling to the 
Fmoc deprotected resin required 4 equivalents (eq) amino acid in ~10 mL DMF, 4 eq 
PyBop, 8 eq HOBT, and a catalytic amount of N-methyl morpholine (~200 µL). Reaction 
vessels were placed on a shaker at room temperature for 1 to 4 hours. The Kaiser test (1 
drop each of 3 solutions: i) 5 g ninhydrin in 100 mL ethanol, ii) 80g of phenol in 20 mL 
of ethanol, and iii) 2 mL of a 1 mM aq. solution of potassium cyanide in 98 mL pyridine) 
was performed after each coupling and deprotection step to monitor the reaction progress. 
110 
If free amine was present, the beads turned blue upon heating for ~1 minute. After each 
coupling step, 1:1 pyridine:acetic anhydride was used to cap any unreacted amines. After 
on-bead conjugation with the G2 dendrimer, the beads were washed 5 times with DMF, 5 
times with methanol, and 15 times with dichloromethane (~5 mL per wash). The resin 
was dried in a dessicator overnight and washed with dicloromethane again prior to 
cleavage. Cleavage in 95% TFA, 2.5% water, 2.5% TIS for 3 hours followed by ether 
precipitation yielded 41 mg orange powder. All amino acid protecting groups were 
removed in the TFA cleavage cocktail.  
Peptide-dendrimer conjugation. A silica gel purified G2 monochloride 
dendrimer containing an Oregon Green tag (Scheme 5-2) was provided by Dr. Mackay 
Steffensen.  
 
Scheme 5-2 
 
 
 
 
 
 
 
 
Substitution of the monochloride core with a secondary amine from the N-terminal 
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N
N
N
HN
NH
N
N
N
N
N
N
N
N
NH
N
N
NH
O
O
H2N
H2N
H2N
H2N
HO
O
OH
O
O
O
OH
O
F
F
O
HN
Cl
C68H95ClF2N22O11
Exact Mass: 1468.72
Mol. Wt.: 1470.07
111 
N,N-diisopropyl ethylamine (DIPEA). The 3368 molecular weight product was filtered 
on a 3000 molecular weight cut-off (MWCO) spin filter (Millipore) according to the 
manufacturer’s protocol, to remove small impurities.  
HPLC of peptides. After 3000 MWCO spin filtration, the peptide was dissolved 
in 4.1 mL (~10 mg/ mL) 5% acetonitrile, 0.1% TFA and filtered through a 0.22 µm 
syringe filter. Sample separation was achieved using a Vydac C18 column with a 5 to 95% 
acetonitrile gradient in aqueous 0.1 % TFA, at a flow rate of 2.5 mL/ min over 30 
minutes. Absorbance was monitored at 254 nm. Further analysis was performed on a 
Beckman 126 analytical HPLC system equipped with a Waters C18 X-Terra column (4.6 
mm X 250 mm) using the same gradient at 1 mL/ min. 
Gel electrophoresis. All gels were poured according to the standard procedure 
for the preparation of sodium dodecyl sulfate (SDS) polyacrylamide gels 116 and run on a 
BioRad Mini Protean 3 vertical mini-gel apparatus. Resolution gels containing 15% 
polyacrylamide prepared with stacking gels containing 5% polyacrylamide were run in 
1X SDS buffer prepared from a 5X stock and were run for 120 minutes at 120 V. 
Samples Coomassie Brilliant Blue R-250 (Fisher Biotech) was used to visualize both 
streptavidin and dendrimer-peptide conjugate. Gels were soaked in the coomassie dye for 
1 hour. To visualize the bands, the gel was immersed in 50 mL destaining solution: 40% 
methanol, 10% acetic acid in water, shaking gently until bands appeared. The destaining 
solution was removed and fresh added occasionally until any background staining was 
removed. A CCD camera was used for recording images. 
MALDI-TOF. Sample solutions (1 µM) were mixed with one of several different 
matrix additives including: α-Cyano-4-hydroxycinnamic acid, 2,4,6-
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trihydroxyacetophenone (THAP, 15 mg/ml in acetonitrile), ferulic acid, aqueous 
ammonium citrate (15 mg/ml), and/ or sinapic acid. The analyte-doped matrix crystals 
were washed 10 times with 5 µL of cold water to remove sodium and potassium ions.  An 
Applied Biosystems (Framingham, MA) Voyager-DE STR mass spectrometer operating 
in positive- and negative-ion mode was used to obtain the mass spectra.  The system is 
equipped with a N2 laser providing 337 nm, 3 ns wide pulses with the accelerating 
voltage maintained at 25 kV for this study.  Delayed extraction (~ 600 ns) mode was 
applied in linear time-of-flight detection.   
Streptavidin addition. Conjugation with streptavidin (Sigma) was carried out in 
5 mM phosphate buffered saline (PBS) at ~6 units streptavidin per 90 nmoles 
biotinylated peptide-dendrimer conjugate, a 3-fold molar excess of the recommended 1 
µg biotin per unit streptavidin. The conjugation reaction was incubated at 27°C for 1.5 
hours.  
Biotin/streptavidin titrations. The concentration of streptavidin was determined 
using the BCA protein assay kit (Pierce). In a 1 mL UV-vis cuvette, 0.5 mg/ mL 
streptavidin was added. The streptavidin was complexed with 2-(4′-hydroxyazobenzene) 
benzoic acid (HABA) dye by adding 2 µg at a time from a 2µg/ µL (10 mM) stock while 
collecting UV-vis spectra after each addition. Sample was mixed thoroughly with a 10 
µL pipet tip prior to each spectral reading. After adding ~7 µg of HABA (binding 
capacity for 244.3 g/mol HABA = 30 nmoles, 7 µg), the sample was spun on a 10,000 
MWCO spin filter to remove any unbound dye. The resulting spectrum was used as the 
starting point for the titration experiment with D-biotin or biotinylated TAT-dendrimer 
conjugate. A 0.1 mg/ mL solution of D-biotin was prepared in water, and added to the 
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streptavidin solution 2 µL (0.2 µg) at a time. Again, samples were mixed thoroughly with 
a 10 µL pipet tip prior to each spectral reading. The procedure was repeated for TAT-
dendrimer conjugate in place of D-biotin. 
Both HABA-streptavidin and D-biotin-streptavidin absorb at 330 nm, but the 
release of HABA from streptavidin produces a decrease in absorbance at 500 nm 
corresponding to the rate of biotin-streptavidin bond formation. A plot of µg biotin added 
vs. absorbance at 500 nm yielded a binding curve. Binding curves for conjugate-
streptavidin were compared to that of biotin-streptavidin.  
 
RESULTS AND DISCUSSION 
 
 Synthesis.  The possibility that unconjugated (dendrimer-free) peptide impurities 
(capable of competing with conjugate for streptavidin-binding sites) were present in the 
sample was a concern. The presence of biotinylated peptide failure sequences (capped 
intermediates from incomplete coupling reactions), if present, would greatly diminish the 
value of the gel electrophoresis results presented herein as they would contain biotin for 
streptavidin ligation but no dendrimer.  
MALDI-TOF. As shown in Figure 5-1, the MALDI-TOF spectrum of crude 
reaction material, post ether precipitation indicated the presence of at least three 
impurities at m/z = 1468, 1535, and 2017. The target MW appears at m/z = 3369, and the 
expected [M+H]+ m/z = 3369 as shown in Scheme 5-3 (calculated MW = 3368). 
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Figure 5-1. MALDI-TOF corresponding to solid-phase synthesized crude peptide-
dendrimer conjugate post ether precipitation. 
 
Scheme 5-3 
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In an effort to separate the low molecular weight impurities from the desired product at 
m/z = 3369 in Figure 5-1, the product was filtered on a Millipore 3000 molecular weight 
cutoff (MWCO) centrifugal filter device. Spin filtration on a 3000 MWCO spin filter 
successfully separated the 1468 molecular weight (MW) impurity. The filtrate from the 
spin column was analyzed by MALDI-TOF, and the resulting spectrum is shown in 
Figure 5-2. A small amount of 1535 MW product was also observed in the filtrate.  
 
Figure 5-2. MALDI-TOF corresponding to crude peptide-dendrimer conjugate filtrate      
from a 3000 MWCO centrifugal spin filter 
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“Mini-PEG” linker coupling. One major impurity present after peptide cleavage 
was the result of an attempted peptide coupling step with a 8-amino-3,6-dioxaoctanoic 
acid (“mini-PEG”) chain purchased in purified form from Peptides International. The 
“mini-PEG” was to serve as a biocompatible linker between the peptide and dendrimer. A 
positive Kaiser test indicated that the “mini-PEG” coupling failed.  
Test cleavage to monitor “mini-PEG” coupling progress. Scheme 5-4 shows 
the structure and formula corresponding to the peptide product formed from this test 
cleavage. MALDI-TOF data from this small sample of cleaved intermediate supported 
Kaiser test results indicating that the “mini-PEG” coupling was unsuccessful. Figure 5-3 
shows the MALDI-TOF results corresponding to the crude product formed from the test 
cleavage (MALDI-TOF: [M+H]+ m/z expected for successful PEG coupling = 1840.2, 
not found; m/z [M+H]+ expected for no mini-PEG coupling = 1695.1, observed = 
1695.3). All other peaks present at this intermediate stage in the synthesis, were not 
found in the final product, and were attributed to imputities present only in the test 
cleavage reaction mixture.  
Scheme 5-4 
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It should be noted that the two major impurities found after peptide-dendrimer cleavage 
with m/z [M+H]+ of 1467.7 and 1534.8, shown in Figure 5-2, were not present at the test 
cleavage stage as they likely would be if they had originated from failure sequences 
(short peptide impurities that have been capped during peptide synthesis as a result of 
incomplete coupling reactions).   
 
Figure 5-3. MALDI-TOF corresponding to peptide intermediate shown in Scheme 5-4 
(calculated m/z [M+H]+ = 1695.1) from the test cleavage. 
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to both species the impurity contributed no impediment to our main synthetic goal which 
was to accomplish and demonstrate megamer formation. Scheme 5-3 (mentioned above) 
shows the structure and formula corresponding to desired peptide-dendrimer conjugate, 
and Scheme 5-5 shows the structure and formula corresponding to the “mini-PEG” 
containing peptide-dendrimer conjugate byproduct. 
 
 
Figure 5-4. MALDI-TOF corresponding to target peptide-dendrimer (calculated m/z 
[M+H]+ = 3368.9) and “mini-PEG” containing product (calculated m/z [M+H]+ = 
3457.1). 
 
 
 
 
 
Mass-to-Charge (m/z) 
3200 3340 3480 3620 3760 3900 
0 
50 
100 
%
 In
te
ns
ity
 
3368.82 
3456.89 
119 
Scheme 5-5 
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HPLC purification of TAT peptide. Two of the four HPLC fractions that were 
collected over the 30 minute gradient were yellow in color, one with a retention time of 
5.7 minutes, and the other with a retention time of 8.2 minutes (Figure 5-5). The collected 
fractions from several injections were pooled, and the two resulting samples were dried in 
vacuo for MALDI-TOF analysis. The sample corresponding to elution at 8.2 minutes 
contained predominately two species, one corresponding to the desired target (MW = 
3368 g/ mol), and the other corresponding to a “mini-PEG” containing byproduct (MW = 
3456 g/ mol).   
 
Figure 5-5. Preparatory HPLC trace of crude TAT-dendrimer conjugate. 
 
 
co-eluting peptide-
dendrimer conjugates dendrimer  
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Following peak identification by MALDI-TOF, the desired product (co-eluting with the 
“mini-PEG” containing side product) was run by analytical HPLC, resulting in one 
predominant peak around 14 minutes (Figure 5-6). 
 
 
Figure 5-6. Analytical HPLC trace of semi-purified TAT-dendrimer conjugate. 
 
 
Solution phase peptide-dendrimer conjugation. In an effort to increase yields, 
the TAT sequence was re-synthesized and cleaved from the resin after the isonipecotic 
acid coupling. Boc-protected Ipn was provided by Dr. Emily Hollink. Boc was released 
upon TFA cleavage affording the secondary amine in 75% yield. The attempted 
nucleophilic aromatic substitution reaction between the terminal secondary amine and the 
G2 monochloride dendrimer proceeded over many days, and never reached completion 
according to reverse-phase thin layer chromatography and MALDI-TOF. Several solvent 
systems and reaction conditions such as the addition of heat along with the addition of 
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denaturants like Tween-20 were employed to speed the reaction progress with no 
observed effect. Sterics may play a large role in the poor yields obtained in many of the 
biopolymer-dendrimer couplings discussed throughout this work. Figure 5-7 shows the 
MALDI-TOF result indicating formation of the desired product at m/z = 3369, as 
expected. The resulting product afforded one conjugate rather than two as above, but in 
much lower yield. 
 
Figure 5-7.  MALDI-TOF corresponding to product formed from the solution-phase 
synthesis of the TAT peptide dendrimer conjugate. 
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yields. The preparation of a dichloride core from the reaction of an HPLC-purified 
piperazine-activated dendrimer with cyanuric chloride and subsequent 
conjugation.attempts are discussed below. This dendrimer would have yielded a construct 
amenable to further modifications through a maleimide functionality also present on the 
dendrimer, however, the attempted site of peptide conjugation was at the dichloride core 
of a dendrimer resulting from the reaction of the purified G2 dendrimer in Scheme 5-3 
with cyanuric chloride, on ice, in THF containing a small amount of DIPEA. The poor 
conjugation yields observed with dichloride triazine-based dendrimers suggest steric 
hindrance could be the primary cause of low yields. A longer glycine chain separating the 
peptide from the dendrimer might have been beneficial for eliminating some of the steric 
hinderance thought to be causing poor reactivity. 
 
Scheme 5-6 
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Gel electrophoresis. The gel shown in Figure 5-8 shows that a high molecular 
weight complex is formed (lane 3) upon the addition of conjugate to the streptavidin, 
which otherwise traveled through the SDS gel as a monomer at ~13 kDa. The two 
preceeding lanes contained 0.1 µg (lane 2) and 0.5 µg (lane 1) streptavidin. Comparison 
with the molecular weight marker reveals that the higher molecular weight band 
corresponds to a molecular weight ≅ 66 kDa (albumin standard) by gel electrophoresis 
indicating the presence of tetrameric streptavidin. Noted previously, biotin or biotinylated 
molecules stabilize the tetrameric form of streptavidin. In order to determine that the 
tetrameric streptavidin was bound to conjugate, the sample was titrated with free biotin, 
which has a higher affinity for streptavidin, and a much smaller dissociation constant (10 
-15 M). 
 
 
 
 
 
 
 
 
 
Figure 5-8. Coomassie stain of a 15% SDS polyacrylamide gel of streptavidin and 
megamer. 
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The gel shown in Figure 5-9 revealed a downward band shift indicating a decreased 
molecular weight of the tetrameric streptavidin as D-biotin replaced TAT-dendrimer 
conjugate. Lane 1 was loaded with the megamer prior to addition of D-biotin. Lanes 2 
through 6 illustrated the removal of higher molecular weight conjugate and replacement 
with lower molecular weight D-biotin indicated by a downward band shift in the 66 kDa 
region. Importantly, the lower region of the gel showed an increase in fluorescent signal 
arising from an increase in the release of TAT-dendrimer bioconjugate from the 
streptavidin. Two bands were seen corresponding to the bioconjugate released, 
presumably because 2 major products (with and without mini-PEG) were formed. Lane 7 
was loaded with D-biotin, and no bands were observed, as expected. Lane 8 contained 
TAT peptide-dendrimer conjugate. Lane 9 was loaded with streptavidin, and because 
there was no D-biotin present to stabilize the teramer, it is observed in the monomeric 
form ~13 kDa. Lane 10 contained molecular weight marker (Amersham wide range). The 
increase in coomassie uptake as biotin replaces the bioconjugate on streptavidin is 
thought to be due to the increased accessibility of the hydrophobic dye to streptavidin.  
Spectral titrations.  Figure 5-8 shows 2 different titrations. The top spectrum is a 
titration of streptavidin with HABA, which absorbs maximally ~350 nm. The 
streptavidin-HABA and streptavidin-biotin complexes also absorb ~350 nm, but the 
streptavidin-HABA complex is unique in that it absorbs at 500 nm. Unbound HABA does 
not absorb at 500 nm, allowing for spectral detection of HABA release as biotin (which 
has a much higher association constant with streptavidin than HABA) or biotinylated 
species bind to streptavidin. 
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Figure 5-9. Coomassie stain of a 15% SDS polyacrylamide gel of megamer titrated from 
right to left with D-biotin. Fluorescence observed across the lower portion of the gel 
increases as the bioconjugate is released from the streptavidin. 
 
 
Shown in Figure 5-10, when 2 µg HABA has been added to the streptavidin, an 
increase in A350 is observed. Likewise, an increase is observed when another 2 µg has 
been added, shown as 4 µg HABA in Figure 5-10. After the addition of another 2µg 
HABA (6 µg total), the sample was filtered to remove excess HABA. This sample was 
used as the starting material for the next titration. By titrating in biotin, shown in the 
bottom series of spectra, release of HABA is observed at A500. 
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Figure 5-10.  Spectral results from the titration of streptavidin (A) with HABA and (B) 
with TAT-dendrimer conjugate resulting in HABA release and a corresponding decrease 
in A500. 
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Figure 5-11 compares the rates of HABA release upon the addition of D-biotin 
with that of biotinylated TAT-dendrimer conjugate. As shown, there is a rapid rate of 
HABA release when titrating with D-biotin that levels off at approximately 10 µg D-
biotin added. Conjugate on the other hand binds to streptavidin at a much slower rate. D-
biotin maximally bound to the streptavidin ~ 10 µg or 41 nmoles, very close to the 
theoretical 45 nmole binding capacity. The binding capacity was determined according to 
the following calculation:  
 
(0.75 mg/ 66,000 mg/mmol) X (1 mmol/ 1,000,000 nmol) = 11.36 nmoles tetramer 
1 tetramer binds 4 eq. biotin, therefore, 11.36 X 4 = 45.44 nmoles 
 
Maximal binding of streptavidin, on the other hand, took place at ~ 60 µg or 18 nmoles 
TAT-dendrimer conjugate indicating incomplete megamer formation possibly due to 
sterics.  
MALDI-TOF. Protein subunits typically break apart using MALDI-TOF, so that 
only very stable subunit interactions are detected. In most cases, as is the case for 
streptavidin, the typical MALDI process will yield signal for the monomer only. Figure 
5-12 shows the MALDI result for streptavidin alone, showing up at the monomer 
molecular weight ~13,000. 
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Figure 5-11.  HABA-release curves of µg D-biotin ( ) or biotinylated TAT-
dendrimer conjugate ( ) vs. A500. 
 
 
  As observed with the gels, however, the addition of biotinylated conjugate 
resulted in stabilization of the tetrameric form, and the protein was able to remain intact 
after being subjected to the MALDI process. Evidence of this is shown in Figure 5-13, 
where the the dimer ~26 kDa is evident as well as a trimer, presumably formed during the 
MALDI process ~39 kDa.  Also evident by MALDI-TOF is the addition of new trimeric 
and tetrameric forms of the protein indicating megamer formation. In Figure 5-14, 
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CONCLUSIONS 
 
We show that dendrimers derivatized with biotin can assemble in the presence of 
streptavidin, a 60 kDa tetramer that binds 4 biotin molecules. While the non-covalent 
assembly is difficult to probe using MALDI-TOF, gel electrophoresis and titration 
experiments suggest that the assembly occurs spontaneously. The resulting 
macromolecule is naturally monodisperse, and facilitates the tetravalent display of 
dendrimers. Gel data suggests that at least some of the streptavidin was completely bound 
in the presence of an excess of TAT conjugate because four distinct band shifts were 
observed indicating the presence of four distinct streptavidin tetramers.  
Dendrimer constructs with similar topologies are referred to as megamers, but 
none to date have relied on the interaction of a protein-ligand interaction. The megamer 
strategy looks promising for drug delivery because it is allows for chemically 
interchangeable surface groups or targeting and transport moeities that are located on the 
dendrimer’s periphery to be “plugged into” a biocompatible macromolecular carrier. The 
size of the final construct exceeds the necessary molecular weight for the exploitation of 
EPR in tumors.   
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CHAPTER VI 
SUMMARY AND CONCLUSIONS 
 
This work illustrates the challenges involved in forming bioconjugates between 
dendrimers and ssDNA or peptides. Methods for purification of ssDNA-dendrimer 
constructs have been presented and techniques for the elucidation of solution-phase and 
solid-supported behavior of these conjugates have been discussed. Skepticism regarding 
the nature of the interaction between the cationic dendrimers and anionic ssDNA has 
been addressed. Although electrostatic binding with DNA may still exist in these 
systems, it may serve to enhance the rate of covalent bond formation.  
The proposed covalent linkage could offer increased protection to the attached 
oligonucleotides, for use in gene therapy, since it is less likely to dissociate. Variations of 
the reported conjugates could be a versatile and cost effective addition to many 
nanofabrication techniques that rely on hybridization including the preparation of more 
effective biosensors, self-assembly of more geometrically or topologically complex 
nanostructures, and development of more powerful DNA-computation strategies.  
Hybridization or duplex DNA formation via Watson-Crick base-pairing between 
ssDNA and ssDNA-dendrimer conjugates is essential for all of the applications 
mentioned herein. Thus it is of great interest that these ssDNA-dendrimer constructs have 
been successfully hybridized with ssDNA attached to a gold surface. This result indicates 
that hybridization is not adversely affected by the presence of a covalently attached 
dendrimer and further demonstrates their potential as signal enhancement techniques for 
measuring the extent of hybridization.  
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Chapter III discussed how disulfide-linked conjugates were shown to increase the 
sensitivity of surface hybridization studies using surface plasmon resonance.  Due to the 
homogenous nature of these constructs they are also amenable to solution phase 
analytical techniques like gel electrophoresis, mass spectrometry, and a variety of 
automated spectral techniques for rapid analysis. Homogeneous detection capabilities 
allow for the opportunity to conduct real-time spectral analysis of several interactions 
between DNA and various other biomolecules. 
Chapter IV discussed solution phase hybridization studies and the melting 
temperature of a 25-mer was compared to that of the dendrimer-bound analog. Results 
revealed that the dendrimer does not necessarily preclude duplex DNA formation as 
some hyperchomicity is detected upon the addition of complement. However, the 
solution-phase experiments do suggest that the DNA and dendrimer are interacting in 
some way resulting in an increased A260 relative to ssDNA prior to the addition of 
complement. The ability of enzymes to function in the presence of dendrimers based on 
melamine, as demonstrated in Chapter IV, is hopeful as it suggests that the analysis of 
enzyme-substrate interactions and assays for sequence specificity using these constructs 
as scaffolds will be possible. 
Chapter V describes the self-assembly of peptide dendrimer conjugates around a 
streptavidin tetramer. Binding curve results indicate that the larger conjugate does not 
bind as quickly as D-biotin, and does not achieve maximal binding efficiency. Gel 
results, however, show that 4 distinct streptavidin tetramers were formed, suggesting that 
megamer formation was successful. Due to their size, scalability, and ease of preparation, 
megamers serve as an attractive target for drug delivery studies. 
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APPENDIX A 
List of abbreviations 
A adenine,  (purine base in DNA) 
BAM HI sequence specific enzyme that cleaves double-stranded DNA (endonuclease) 
Boc butoxycarbonyl (amine protecting group) 
C cytosine (pyrimidine base in DNA) 
DIPEA N,N-diisopropyl ethylamine (Hunig's base) 
DMT dimethoxy trityl protecting group 
DMF N,N-dimethylformamide 
DTT dithiothreitol 
EDTA ethylenediaminetetra acetic acid 
EMCS N-(6-maleimidocaproxy)succinimide 
EPR enhanced permeability and retention 
EXO III enzyme that cleaves double-stranded DNA from the 3' terminus (exonuclease) 
Fmoc fluorinylmethoxycarbonyl (amine protecting group) 
FTIR fourier transform infrared 
G guanine (purine base in DNA) 
GMBS N-(4-maleimidobutyryloxy)succinimide 
HABA 2-(4'-hydroxyazobenzene) benzoic acid  
HPLC high performance liquid chromatography 
m/z mass-to-charge ratio 
MALDI-TOF matrix-assisted laser desorption ionization time-of-flight 
MWCO molecular weight cutoff 
NMR nuclear magnetic resonance 
PAGE polyacrylamide gel electrophoresis 
PAMAM polyamidoamine 
PEG polyethylene glycol 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SPDP succinimidyl 3-(2-pyridylthio)propionate  
SPPS solid-phase peptide synthesis 
SPRi surface plasmon resonance imaging 
SSMCC sulfosuccinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate 
T thymine (pyrimidine base in DNA) 
TAT transactivator of transcription (peptide sequence from the TAT protein) 
TBE tris(hydroxymethyl) aminomethane-borate ethylenediaminetetra acetic acid buffer 
TCEP 2-carboxyethylphosphine 
TEAA triethylamine acetate 
TEMED N,N,N',N'-tetramethylethylenediamine 
TFA trifloroascetic acid 
THAP 2,4,6-trihydroxyacetophenone 
THF tetrahydrofuran 
Tris-HCl tris(hydroxymethyl) aminomethane-hydrochloric acid buffer 
Tween-20 surfactant, sorbitan mono-9octadecenoate poly(oxy-1,1-ethanedlyl)  
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